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AMENDED REPORT- Version 33a of the Newborn Screening Annual Summary Report reflects a correction in domestic and foreign cutoff 
statistics (pages 9-14) and the sample table in Figure 4 (page21). Version 33b corrects the title of Figures 2 & 3 (page 5).
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2016 Shipping Schedule for Newborn Screening Quality Assurance Program Proficiency Testing (PT)  
and Quality Control (QC) Materials*
*Note that shipment dates are subject to change due to unexpected temporary CDC closures
PT Panels Enrollment Deadline Shipping Date Data Deadline Report Available
Quarter 1 November 1, 2015 January 11 February 8 February 12
Quarter 2  (UDOT**) March 1 April 4 April 25 May
Quarter 3 May 1 July 11 August 8 August 12
Quarter 4 August 1 October 3 October 31 November 4
** Domestic Laboratories only
SECOND-TIER CONGENITAL ADRENAL HYPERPLASIA, CYSTIC FIBROSIS DNA MUTATION DETECTION, LYSOSOMAL STORAGE DISORDERS,  
ANTI-TOXOPLASMA ANTIBODIES, T-CELL RECEPTOR EXCISION CIRCLE, AND  X-LINKED ADRENOLEUKODYSTROPHY PT PANELS ONLY
CAH, CFDNA, LSD, 
Toxo, TREC, & XALD 
PT Panels
Enrollment Deadline Shipping Date Data Deadline Report Available
Quarter 1 November 1, 2015 January 11 February 8 March
Quarter 2 
(No CAH or XALD)
March 1 April 4 May 2 May
Quarter 3 May 1 July 11 August 8 August
Quarter 4 August 1 October 3 October 31 November
ANTI-HIV-1 ANTIBODIES  PT PANELS
HIVPT & HIVQC Enrollment Deadline Shipping Date Data Deadline Report Available
Quarter 1 
(HIVPT and HIVQC)
November 1, 2015 January 12 February 15 March
Quarter 2 
(HIV PT only)
March 1 April 11 May 9 May
Quarter 3
(HIVPT and HIVQC)
May 1 July 12 August 8 August
Quarter 4
(HIV PT only)
August 1 Tues: October 11 November 7 November
SICKLE CELL AND OTHER HEMOGLOBINOPATHIES PT PANELS
Hemoglobinopathies  
PT Panels
Enrollment Deadline Shipping Date Data Deadline Report Available
Panel 1 Waiting List January 11 February 8 February
Panel 2 Waiting List May 2 May 30 June
Panel 3 Waiting List October 3 October 31 November




Enrollment Deadline Shipping Date Data Deadline Report Available
Set 1 November 1, 2015 January 11 April 1 July 2016
Set 2 May 1 July 12 October 1 February 2017
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Introduction
Newborn screening is one of the most successful pre-
ventative public health programs in the United States. 
State public health laboratories or their associated 
laboratories routinely screen dried blood spot (DBS) 
specimens collected from newborns shortly after birth 
for certain genetic, metabolic, or endocrine disorders. 
Effective screening, along with follow up, diagnosis, 
and intervention, helps prevent mental retardation and 
premature death caused by these inherited diseases. 
Healthcare professionals collect DBS specimens from 
more than 98% of all newborns in the United States. The 
Centers for Disease Control and Prevention’s (CDC) New-
born Screening Quality Assurance Program (NSQAP) as-
sists newborn screening laboratories with these testing 
processes.
NSQAP produces certified DBS materials for proficiency 
testing (PT) and quality control (QC) analysis, works to 
improve the quality and scope of laboratory services, 
and provides consultative assistance to laboratories. 
Both state-operated and private newborn screening 
laboratories process large numbers of DBS specimens 
daily. NSQAP helps newborn screening laboratories 
ensure that testing accurately detects disorders, does 
not delay diagnosis, minimizes false positive reports, 
and sustains high-quality performance. Our job is to 
serve our participating newborn screening laboratories. 
We welcome comments and suggestions about how we 
can better serve participants’ needs at NSQAPDMT@cdc.
gov.
For more than 35 years, NSQAP, with its cosponsor the 
Association of Public Health Laboratories (APHL) has 
researched the development of DBS screening test 
materials and has assisted laboratories with DBS-related 
quality assurance (QA). NSQAP primarily supports U.S. 
newborn screening laboratories, but also allows private 
and international laboratories to enroll in the program. 
Participation is voluntary. NSQAP provides QA services 
for the core (primary) and secondary conditions listed in 
the U.S. Recommended Uniform Screening Panel (RUSP) 
[1]. These disorders include, but are not limited to, the 
following: 
• congenital hypothyroidism
• congenital adrenal hyperplasia
• galactosemia
• phenylketonuria








• urea cycle disorders
• fatty acid oxidation disorders
• organic acid metabolic disorders
• X-linked adrenoleukodystrophy (XALD)
• severe combined immunodeficiency (SCID)
Over the years, NSQAP has grown substantially. In 2015, 
active program participants included 625 newborn 
screening laboratories in 77 countries (at least one labo-
ratory per country) (Figure 1). Of these laboratories, 534 
participated in PT (Figure 2) and 481 in QC (Figure 3). 
The program distributed DBS materials for 52 analytes 
to participating laboratories (Figures 2–3). 
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To offer more specialized services, NSQAP works with 
the Biochemical Mass Spectrometry Laboratory (BMSL), 
the Newborn Screening Translation Research Initia-
tive (NSTRI), and the Molecular Quality Improvement 
Program (MQIP). 
BMSL offers newborn screening tandem mass spec-
trometry (MS/MS) services, education, and research 
opportunities as well as overseeing amino acids, acyl-
carnitines, biotinidase, total galactose (TGal), galactose-
1-phosphate uridyltransferase (GALT), and the filter pa-
per evaluation program. MQIP was created to enhance 
molecular testing assistance provided to newborn 
screening laboratories. MQIP also offers the Molecular 
Assessment Program (MAP) which conducts onsite 
visits to U.S. newborn screening laboratories. These 
visits encompass all components of molecular testing 
procedures, including program-tailored guidance for 
laboratory-specific needs and assistance in evaluating 
ongoing and future molecular testing procedures.  
MQIP oversees the cystic fibrosis DNA mutation detec-
tion (CFDNA) PT program. NSTRI is an ongoing collabo-
ration between the CDC Foundation and CDC’s New-
born Screening Molecular Biology Branch (NSMBB) and 
it developed the PT program for T-cell receptor excision 
circle (TREC) and lysosomal storage disorders (LSD)[2].
This report summarizes all phases of NSQAP’s PT activi-
ties and all QC data reported in 2015.
5Summary Report
Figure 2.  Number of Participants in Proficiency 
Testing Program, 2015  Total-534
Figure 3.  Number of Participants in Quality 
Control Program, 2015 Total- 481
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2015 NEWBORN SCREENING PROGRAM HIGHLIGHTS
January 
BMSL shipped the first X-linked adrenoleukodystrophy 
(XALD) QC materials containing 24:0- and 26:0-lysophos-
phatidylcholines. Summary data for these materials are 
included in the QC tables of this report. 
February 
BMSL and APHL convened a two-day workshop titled Na-
tional Conversation: Tandem Mass Spectrometry in Newborn 
Screening. State newborn screening laboratorians, lab 
directors, and MS/MS directors attended the meeting.
March  
In cooperation with APHL, MQIP hosted its annual New-
born Screening Molecular Training Workshop. This dynamic 
hands-on workshop included lectures and laboratory 
training activities directly related to the detection of new-
born disorders using molecular methods. 
April 
BMSL shipped a nine-level set of QC materials to enrolled 
NSQAP participants. These materials are used to assess the 
linearity of newborn screening MS/MS assays and cover  
34 amino acid and acylcarnitine analytes. 
MQIP hosted the APHL Molecular Subcommittee face-
to-face meeting on the CDC campus in Atlanta. Informa-
tion from these meetings is used to improve molecular 
services to NSQAP participants. 
BMSL hosted a five-day workshop: Newborn Screening by 
Tandem Mass Spectrometry (MS/MS): A Hands-On Course 
in Understanding Laboratory Issues and Interpreting Test 
Results. CDC co-sponsored the workshop at CDC’s labora-
tories in Atlanta, GA. 
NSTRI and APHL convened a two-day workshop: New-
born Bloodspot Screening for Pompe Disease and Other 
Lysosomal Storage Disorders. Attendees included physi-
cians and scientists from newborn screening programs, 
medical centers, federal agencies, and APHL. You can view 




NSQAP and APHL hosted the QA/QC Subcommittee of 
the Newborn Screening and Genetics in Public Health 
Program in Atlanta. This subcommittee provides guid-
ance to NSQAP on procedures, policies, and activities for 
quality assessment of laboratory testing. Input from this 
subcommittee enhances our continuing efforts to serve 
our participants. 
June  
Inter-laboratory Comparison of Assays to Measure SMN2 
Copy Number in Dried Blood Spots from Patients with Spinal 
Muscular Atrophy, Carriers, and Controls was presented at 
the annual CDC Division of Laboratory Sciences Summer 
Symposium. The presentation focused on confirmatory 
testing and genetic characterization of Spinal Muscular 
Atrophy screen-positive results on dried blood spots.  
July 
NSTRI participated in the APHL NewSTEPs meeting on 
newborn screening for SCID. Dr. Francis Lee presented an 
overview of the technical and scientific support offered 
by the CDC including consultations, trainings,  and access 
to reference materials. NTSRI guest researcher Dr. Lisa 
Kobrynski, Marcus Professor of Immunology and director 
of the Jeffrey Modell Foundation Center for Excellence 
at the Emory University School of Medicine, provided an 
overview of the definitions and clinical presentations as-
sociated with SCID. 
September 
MAP completed four site visits in 2015. These onsite visits 
assess a state newborn screening laboratory’s molecular 
testing program. To request a MAP visit, go to the New-




PT programs for glucose-6-phosphate deficiency (G6PD) 
and XALD launched. Email NSQAPDMT@cdc.gov for more 
information or to register for these  PT programs.
7Summary Report
FILTER PAPER
NSQAP evaluates absorption characteristics of all filter 
paper lots that have Food and Drug Administration 
(FDA) approval as a newborn screening collection 
device [3]. The manufacturers must establish their own 
parallel evaluation. NSQAP’s evaluations are an impar-
tial and voluntary service offered as a function of our 
QA program; they do not constitute endorsement of 
any product.
The disk punched from DBS specimens is a volumetric 
measurement that requires a high degree of unifor-
mity among and within production lots. NSQAP uses 
an isotopic method developed at CDC to evaluate and 
compare different lots of filter paper. Mean counts 
per minute of added radioisotope-labeled thyroxine 
(T4) contained within a 3.2-mm disk are equated with 
the serum absorption volume of the disks made from 
washed intact red blood cells (RBCs). A description 
of the method is in the latest version of the Clinical 
and Laboratory Standards Institute (CLSI) Standard 
NBS01-A6, Blood Collection on Filter Paper for Newborn 
Screening Programs [3]. 
FDA-approved newborn screening filter paper manu-
facturers (GE Healthcare Biosciences Corporation and 
PerkinElmer Health Sciences) provide NSQAP with 
statistically valid sample sets of unprinted filter paper 
from each production lot. Tables 1 and 2 show serum 
absorption volumes from the last 10 lots of these two 
filter paper sources. The published and standardized 
acceptable serum absorption volume per 3.2-mm disk 
is (mean value and 95% confidence interval [CI]) 1.44 ± 
0.20 μL for washed intact RBCs [3]. The testing results 
provided in Tables 1 and 2 are for information purposes 
only. Each mean value was within the acceptable range 
for the matrix used. All lots were homogeneous (i.e., the 
measured within-spot, within-sheet, and among-sheets 
variances were within acceptable limits).
Filter paper lots used in the CDC production of QC and 
PT specimens distributed in 2015 were W112, W113, 
and W141 of Whatman 903.
Table 1. PerkinElmer 226 Specimen Collection Paper Filter Paper Absorption Characteristics by Lot Number  





Serum Absorption Volume (µL)  
per 3.2mm (1/8”) punch
Absorption Time  (sec) Spot Diameter  (mm)
(month/year) Avg StDev Avg StDev Avg StDev
105178 Aug-15 1.46 0.09 7.8 1.1 15.9 0.6
104568 Mar-15 1.56 0.10 10.1 2.1 15.9 0.7
103649 Mar-14 1.53 0.10 9.7 3.1 15.7 0.7
102928 Aug-13 1.38 0.09 8.5 0.9 16.1 0.5
102277 Dec-12 1.47 0.11 13.0 4.9 15.8 0.6
101535 Apr-12 1.49 0.08 14.7 3.1 15.7 0.5
100535 May-11 1.45 0.08 8.9 2.2 15.7 0.5
0120201 Apr-10 1.47 0.11 14.0 3.7 16.0 0.6
9461001 Feb-10 1.53 0.09 8.8 1.8 15.4 0.6
8040201 Feb-08 1.60 0.10 7.2 1.8 15.6 0.6
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Table 2. Whatman 903 Specimen Collection Paper Filter Paper Absorption Characteristics by Lot Number 




Serum Absorption Volume (µL) 
per 3.2mm (1/8”) punch
Absorption Time (sec) Spot Diameter  (mm)
(month/year) Avg StDev Avg StDev Avg StDev
W152 Aug-15 1.37 0.09 15.8 2.4 16.2 0.6
W151 Aug-15 1.39 0.08 15.2 2.6 16.2 0.8
W142 Apr-15 1.46 0.08 11.0 2.2 16.0 0.7
W141 Mar-14 1.53 0.10 13.8 3.6 15.9 0.6
W131 Aug-13 1.40 0.07 10.4 1.4 16.1 0.5
W122 May-13 1.41 0.11 14.8 2.9 16.3 0.5
W121 Jan-13 1.49 0.09 13.7 3.8 16.0 0.6
W113 Mar-12 1.44 0.08 9.9 2.0 15.8 0.6
W112 Oct-11 1.38 0.13 12.9 2.1 16.0 0.5
W111 Feb-11 1.42 0.08 10.2 1.5 16.1 0.5
PROFICIENCY TESTING
NSQAP distributes PT materials three times a year.  All 
PT panels consist of five blind-coded, 75-μL DBS speci-
mens. Specimen sets are packaged in a zip-closed, met-
alized bag with desiccant, along with instructions for 
analysis and reporting data. These specimens provide 
an independent, external assessment of each labora-
tory’s performance. 
PT MATERIALS AND METHODS
NSQAP certifies PT specimens for homogeneity, accu-
racy, stability, and suitability for newborn screening as-
says. The PT analytes include: 17α-hydroxyprogesterone 
(17OHP), T
4
, thyroid-stimulating hormone (TSH), 
biotinidase (Bio), TGal, GALT, G6PD, immunoreactive 
trypsinogen (IRT), arginine (Arg), citrulline (Cit), leucine 
(Leu), methionine (Met), phenylalanine (Phe), succinyl-
acetone (SUAC),tyrosine (Tyr), and valine (Val), low free 
carnitine (C0(L)), C3, C3DC, C4, C4OH, C5, C5:1, C5OH, 
C5DC, C6, C8, C10, C10:1, C10:2, C14, C14:1, C16, C16OH, 
C18, C18:1, and C18OH, X-linked adrenoleukodystrophy 
(XALD).
• All PT specimens are prepared from whole blood
of 50% hematocrit. PT materials are produced from
single donors.
• Purified analytes or unaltered donor blood are
used for PT enrichments. Enrichments made with
purchased or custom-synthesized acylcarnitines
are based on weighed quantities. Small variances 
in enrichments and recoveries might result from 
impurities in the purchased (synthesized) materials 
and endogenous analyte concentrations.
• Congenital hypothyroidism PT specimens are




depletion of the base serum.
• TGal materials are enriched with galactose and
galactose-1-phosphate, allowing measurement
of both free galactose (galactose alone) and total
galactose (free galactose plus galactose present as
TGal).
• Biotinidase PT pools are made using heat-treated
serum combined with compatible donor RBCs.
• Deficient GALT PT specimens are made using a
50/50 saline/serum solution combined with com-
patible washed RBCs and then heat-treating the
pool.
• Low free carnitine (C0(L)) materials are produced
by washing fresh RBCs at least six times and then
combining with charcoal-stripped serum.
• CFDNA PT materials are made with blood from indi-
vidual donors who express CF mutations.
• Hemoglobin specimens are made from individual
umbilical cord blood units.
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PT DATA HANDLING
Participants submit PT data and clinical assessments 
through the NSQAP data reporting website or by email. 
Laboratories that submit results before the data-re-
porting deadline will receive an individual laboratory 
evaluation and their data will be included in the data 
summary reports. 
PT CUTOFFS
Participants report the decision level for sorting test 
results as presumptive positive (outside normal lim-
its) from results reported as negative (within normal 
limits) based on their laboratory’s established cutoff 
value. Cutoff values vary among participating labora-
tories because each laboratory establishes its own 
cutoff level. For PT evaluations, the participating 
laboratory’s reported cutoff value is applied to our 
grading algorithm. If no cutoff value is reported for 
a particular analytical result, the grading algorithm 
will default to the NSQAP-assigned working cutoff 
values, which are based on the domestic mean 
cutoff value. (Figure 4)
Tables 3–5 summarize the reported cutoff values 
for domestic and foreign laboratories; the values 
for mean, median, and mode are shown for each 
analyte. Tables 6–9 summarize the mean, median, 
mode, and min/max range for reported domestic 
cutoffs by method. 
Table 3. 2015 Summary of Non-MSMS Cutoff Values for Domestic and Foreign Laboratories 
Domestic 
Analyte N Mean Median Mode Min Max
17OHP (ng/mL serum) 43 33.7 33.0 30.0 7.0 65.0
GALT (U/g Hb) 19 3.2 3.1 3.0 2.0 5.5
IRT (ng/mL blood) 43 66.3 65.0 60.0 35.2 114.9
T
4
 (µg/dL serum) 24 6.1 6.0 5.0 4.0 8.5
TGal (mg/dL blood) 24 10.7 10.0 10.0 6.0 20.0
TSH (µIU/mL serum) 43 30.8 25.0 20.0 19.0 58.0
Phe (µmol/L blood) 6 169.3 166.7 N/A* 133.0 224.2
Foreign
Analyte N Mean Median Mode Min Max
17OHP (ng/mL serum) 167 25.7 20.0 19.8 2.6 110.0
GALT (U/g Hb) 43 3.0 3.1 3.5 1.5 5.3
IRT (ng/mL blood) 137 65.7 65.0 60.0 40.0 99.6
T
4
 (µg/dL serum) 42 6.3 6.0 6.0 1.8 22.0
TGal (mg/dL blood) 116 12.0 10.0 10.0 4.1 30.0
TSH (µIU/mL serum) 231 22.4 20.0 20.0 5.0 45.0
Phe (µmol/L blood) 65 183.4 169.9 121.2 120.0 820.8
*Not Applicable
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Table 4. 2015 Summary of MS/MS Cutoff Values of Domestic Laboratories (µmol/L blood) 
Analyte N Mean Median Mode Min Max
Arg 38 70.2 60.0 50.0 20.0 125.0
Cit 45 55.5 55.0 60.0 18.0 100.0
Leu 46 285.1 281.0 250.0 175.0 400.0
Met 46 74.5 72.5 100.0 35.0 100.0
Phe 51 141.4 140.0 130.0 75.0 182.0
SUAC 30 2.7 2.3 4.5 0.5 5.4
Tyr 52 386.7 338.0 400.0 88.0 850.0
Val 32 293.9 277.0 250.0 200.0 530.0
C0(L) 49 8.81 8.00 8.00 4.00 33.00
C3 50 5.68 6.00 6.30 2.82 8.00
C3DC 22 0.22 0.20 0.20 0.10 0.45
C3DC+C4OH 20 0.57 0.41 0.38 0.25 3.03
C4 46 1.27 1.30 1.40 0.49 1.90
C4OH 20 0.65 0.70 0.70 0.35 1.00
C5 50 0.69 0.66 1.00 0.38 1.20
C5:1 49 0.22 0.16 0.50 0.05 0.60
C5DC 49 0.35 0.32 0.50 0.05 0.80
C5OH 49 0.79 0.80 0.80 0.25 1.18
C6 47 0.39 0.29 0.24 0.16 0.95
C8 50 0.45 0.40 0.35 0.25 0.79
C10 46 0.44 0.41 0.40 0.22 0.80
C10:1 43 0.29 0.30 0.30 0.14 0.45
C10:2 30 0.16 0.12 0.10 0.06 0.50
C14 45 0.75 0.70 0.70 0.26 1.20
C14:1 50 0.61 0.65 0.60 0.17 0.80
C16 47 7.64 7.70 7.00 2.14 10.00
C16OH 50 0.13 0.12 0.10 0.07 0.25
C18 42 2.35 2.28 2.50 0.70 4.00
C18:1 44 3.48 3.00 3.00 2.00 7.00
C18OH 39 0.11 0.10 0.10 0.04 0.26
Table 5. 2015 Summary of MS/MS Cutoff Values of Foreign Laboratories (µmol/L blood) 
Analyte N Mean Median Mode Min Max
Arg 177 56.9 51.0 70.0 10.0 150.0
Cit 194 53.6 50.0 55.0 19.5 200.0
Leu 215 308.7 300.0 300.0 147.0 600.0
Met 210 57.6 55.2 75.0 19.0 121.0
Phe 232 135.8 129.0 120.0 48.0 242.4
SUAC 69 2.4 1.6 1.5 0.1 10.0
Tyr 214 297.1 275.0 400.0 35.0 600.0
Val 199 268.2 260.0 250.0 139.3 470.0
C0(L) 221 11.71 8.80 10.00 3.50 80.00
C3 214 5.30 5.25 6.00 1.80 11.00
C3DC 101 0.31 0.28 0.30 0.04 3.70
C3DC+C4OH 66 0.58 0.50 0.50 0.19 2.20
C4 200 1.01 0.98 1.30 0.31 4.00
C4OH 91 0.60 0.61 0.65 0.05 1.40
C5 223 0.69 0.64 1.00 0.20 2.00
C5:1 192 0.17 0.15 0.25 0.01 0.50
C5DC 216 0.33 0.30 0.35 0.07 1.00
C5OH 191 0.78 0.80 1.00 0.16 2.20
C6 203 0.32 0.25 0.45 0.05 1.50
C8 228 0.36 0.32 0.30 0.07 1.42
C10 215 0.39 0.40 0.40 0.09 1.46
C10:1 188 0.30 0.28 0.30 0.06 2.03
C10:2 125 0.16 0.12 0.10 0.00 0.56
C14 200 0.63 0.60 0.80 0.14 1.50
C14:1 210 0.46 0.42 0.60 0.08 1.30
C16 213 6.62 6.90 7.50 0.51 14.00
C16OH 211 0.13 0.10 0.05 0.02 0.48
C18 199 2.18 2.03 2.50 0.71 5.00
C18:1 189 2.96 3.00 3.50 0.20 5.80
C18OH 163 0.11 0.10 0.10 0.01 2.00
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Table 6. 2015 Domestic Cutoff Summary by Analyte and Method - Hormones and Galactose 
Analyte Method
CUTOFF VALUE
N  Mean Median Mode Min Max 
17OHP
ng/mL serum
ALL METHODS 43 33.7 33.0 30.0 7.0 65.0
AutoDelfia 7 46.6 46.2 N/A* 30.0 65.0
AutoDelfia Neonatal 17-OHP (B024) 17 31.4 33.0 33.0 19.0 40.0




ALL METHODS 43 30.8 25.0 20.0 19.0 58.0
AutoDelfia 24 35.1 30.0 20.0 20.0 58.0




ALL METHODS 24 6.1 6.0 5.0 4.0 8.5
AutoDelfia 8 6.2 6.3 6.5 4.0 8.0
PerkinElmer GSP Neonatal 15 6.1 5.5 5.0 4.0 8.5
TGal
mg/dL blood
ALL METHODS 24 10.7 10.0 10.0 6.0 20.0
Astoria-Pacific 50 Hour Reagent Kit 6 10.4 10.0 10.0 6.5 15.0
Fluorometric manual (e.g. Hill or Misuma) 5 12.8 10.0 10.0 10.0 20.0
PerkinElmer GSP Neonatal 3 11.4 13.0 N/A* 7.3 14.0
PerkinElmer Neonatal Kit 5 8.0 8.0 9.5 6.0 9.5





N  Mean Median Mode Min Max 
GALT
U/g Hb
ALL METHODS 19 3.2 3.1 3.0 2.0 5.5
Astoria-Pacific Neonatal Microplate Reagent Kit 5 2.7 2.9 3.1 2.0 3.1
PerkinElmer Neonatal Kit 13 3.2 3.2 3.0 2.4 4.0
IRT
ng/mL blood
ALL METHODS 43 66.3 65.0 60.0 35.2 114.9
Auto Delfia 25 69.3 66.0 67.0 37.7 114.9
PerkinElmer GSP Neonatal 18 62.1 57.0 55.0 35.2 100.0
*N/A - Not Applicable
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N  Mean Median Mode Min Max 
Arg ALL MS/MS Methods 38 70.2 60.0 50.0 20.0 125.0
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 77.5 75.0 100.0 55.0 100.0
Derivatized - MS/MS non-kit 13 48.3 35.0 30.0 20.0 125.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 19 83.0 100.0 50.0 50.0 125.0
Cit ALL MS/MS Methods 45 55.5 55.0 60.0 18.0 100.0
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 61.6 54.0 N/A* 40.0 100.0
Derivatized - MS/MS non-kit 14 45.0 40.0 40.0 18.0 75.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 59.9 60.0 60.0 50.0 85.0
Leu ALL MS/MS Methods 46 285.1 281.0 250.0 175.0 400.0
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 285.0 281.0 275.0 250.0 325.0
Derivatized - MS/MS non-kit 15 265.3 256.0 300.0 200.0 333.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 297.7 281.5 250.0 175.0 400.0
Met ALL MS/MS Methods 46 74.5 72.5 100.0 35.0 100.0
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 76.0 72.5 N/A 60.0 100.0
Derivatized - MS/MS non-kit 15 62.5 60.0 60.0 35.0 100.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 82.2 82.5 100.0 54.5 100.0
Phe ALL MS/MS Methods 57 144.3 150.0 130.0 75.0 224.2
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 137.6 130.0 130.0 120.0 178.0
Derivatized - MS/MS non-kit 18 136.5 137.0 150.0 99.0 182.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 150.2 157.5 165.0 120.0 180.0
Non-derivatized - MS/MS non-kit 3 115.3 121.0 N/A* 75.0 150.0
SUAC ALL MS/MS Methods 30 2.7 2.3 4.5 0.5 5.4
Derivatized - MS/MS non-kit 10 2.5 2.8 3.3 0.5 5.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 19 2.6 2.0 4.5 1.0 4.5
Tyr ALL MS/MS Methods 52 386.7 358.0 400.0 88.0 850.0
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 307.3 288.0 300.0 200.0 552.0
Derivatized - MS/MS non-kit 17 311.2 300.0 400.0 88.0 442.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 518.4 445.0 850.0 300.0 850.0
Non-derivatized - MS/MS non-kit 3 218.3 204.0 N/A* 91.0 360.0
Val ALL MS/MS Methods 32 293.9 277.0 250.0 200.0 530.0
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 291.3 274.0 250.0 250.0 400.0
Derivatized - MS/MS non-kit 11 269.7 250.0 200.0 200.0 420.0
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 14 317.2 312.5 250.0 250.0 530.0
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N  Mean Median Mode Min Max 
C0(L) ALL MS/MS Methods 49 8.81 8.00 8.00 4.00 33.00
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 11.12 10.00 12.00 10.00 13.00
Derivatized - MS/MS non-kit 18 10.40 5.00 8.00 5.00 33.00
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 6.70 6.50 6.00 4.00 10.00
C3 ALL MS/MS Methods 50 5.68 6.00 6.30 2.82 8.00
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 5.52 5.38 5.00 5.00 6.23
Derivatized - MS/MS non-kit 19 5.01 5.00 5.25 2.82 7.30
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 6.26 6.30 6.30 4.00 8.00
C3DC ALL MS/MS Methods 22 0.22 0.20 0.20 0.10 0.45
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 0.27 0.26 0.35 0.19 0.35
Derivatized - MS/MS non-kit 16 0.20 0.17 0.20 0.10 0.45
C3DC+C4OH ALL MS/MS Methods 20 0.57 0.41 0.38 0.25 3.03
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 19 0.44 0.40 0.38 0.25 0.70
C4 ALL MS/MS Methods 46 1.27 1.30 1.30 0.49 1.90
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 1.08 1.04 N/A* 0.81 1.40
Derivatized - MS/MS non-kit 17 1.16 1.20 1.40 0.49 1.90
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 1.41 1.32 1.30 1.10 1.70
C4OH ALL MS/MS Methods 20 0.65 0.70 0.70 0.35 1.00
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 0.73 0.70 N/A* 0.52 1.00
Derivatized - MS/MS non-kit 14 0.68 0.70 0.70 0.35 1.00
C5 ALL MS/MS Methods 50 0.69 0.66 1.00 0.38 1.20
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.63 0.70 0.70 0.45 0.71
Derivatized - MS/MS non-kit 19 0.65 0.60 0.50 0.38 1.20
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 0.76 0.70 1.00 0.50 1.00
C5:1 ALL MS/MS Methods 49 0.22 0.16 0.50 0.05 0.60
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.20 0.18 0.25 0.15 0.25
Derivatized - MS/MS non-kit 19 0.21 0.14 0.08 0.05 0.60
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 0.25 0.19 0.50 0.06 0.50
C5DC ALL MS/MS Methods 49 0.35 0.32 0.50 0.05 0.80
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.30 0.30 0.30 0.24 0.33
Derivatized - MS/MS non-kit 19 0.18 0.18 0.21 0.05 0.32
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 0.52 0.50 0.50 0.35 0.80
C5OH ALL MS/MS Methods 49 0.79 0.80 0.80 0.25 1.18
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.74 0.70 0.65 0.60 1.00
Derivatized - MS/MS non-kit 19 0.75 0.76 1.00 0.25 1.18
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 0.84 0.85 0.85 0.60 1.05
C6 ALL MS/MS Methods 47 0.39 0.29 0.24 0.16 0.95
Derivatized - MS/MS PerkinElmer NeoGram Kit 7 0.26 0.25 0.24 0.20 0.31
Derivatized - MS/MS non-kit 18 0.34 0.30 0.22 0.16 0.86







N  Mean Median Mode Min Max 
C8 ALL MS/MS Methods 50 0.45 0.40 0.35 0.25 0.79
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.39 0.38 0.38 0.32 0.55
Derivatized - MS/MS non-kit 19 0.39 0.35 0.50 0.25 0.72
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 0.52 0.51 0.60 0.35 0.79
C10 ALL MS/MS Methods 46 0.44 0.41 0.40 0.22 0.80
Derivatized - MS/MS PerkinElmer NeoGram Kit 7 0.38 0.40 0.42 0.27 0.50
Derivatized - MS/MS non-kit 17 0.42 0.40 0.30 0.22 0.80
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 0.49 0.45 0.65 0.22 0.70
C10:1 ALL MS/MS Methods 43 0.29 0.30 0.30 0.14 0.45
Derivatized - MS/MS PerkinElmer NeoGram Kit 7 0.31 0.30 0.30 0.30 0.36
Derivatized - MS/MS non-kit 15 0.25 0.23 0.18 0.17 0.40
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 20 0.31 0.28 0.45 0.14 0.45
C10:2 ALL MS/MS Methods 30 0.16 0.12 0.10 0.06 0.50
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 0.15 0.15 0.15 0.10 0.20
Derivatized - MS/MS non-kit 14 0.18 0.13 0.10 0.06 0.39
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 9 0.16 0.10 0.10 0.07 0.50
C14 ALL MS/MS Methods 45 0.75 0.70 0.70 0.26 1.20
Derivatized - MS/MS PerkinElmer NeoGram Kit 7 0.69 0.70 0.70 0.52 0.78
Derivatized - MS/MS non-kit 16 0.65 0.70 0.70 0.26 0.85
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 0.84 0.75 1.20 0.58 1.20
C14:1 ALL MS/MS Methods 50 0.61 0.65 0.60 0.17 0.80
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.60 0.63 N/A* 0.40 0.77
Derivatized - MS/MS non-kit 19 0.55 0.64 0.65 0.17 0.75
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 0.67 0.67 0.80 0.50 0.80
C16 ALL MS/MS Methods 47 7.64 7.70 7.00 2.14 10.00
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 7.19 7.10 7.00 6.65 7.80
Derivatized - MS/MS non-kit 18 6.67 6.88 8.00 2.14 9.00
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 8.52 8.50 10.00 7.00 10.00
C16OH ALL MS/MS Methods 50 0.13 0.12 0.10 0.07 0.25
Derivatized - MS/MS PerkinElmer NeoGram Kit 8 0.17 0.17 0.12 0.12 0.25
Derivatized - MS/MS non-kit 19 0.13 0.13 0.10 0.08 0.25
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 22 0.11 0.10 0.10 0.07 0.20
C18 ALL MS/MS Methods 42 2.35 2.28 2.50 0.70 4.00
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 2.31 2.25 N/A* 1.89 3.00
Derivatized - MS/MS non-kit 14 1.85 1.83 1.80 0.70 2.50
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 2.70 2.50 3.50 1.55 4.00
C18:1 ALL MS/MS Methods 44 3.48 3.00 3.00 2.00 7.00
Derivatized - MS/MS PerkinElmer NeoGram Kit 6 2.91 2.80 N/A* 2.43 3.50
Derivatized - MS/MS non-kit 16 2.71 2.68 3.00 2.00 3.50
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 21 4.22 3.29 7.00 2.27 7.00
C18OH ALL MS/MS Methods 39 0.11 0.10 0.10 0.04 0.26
Derivatized - MS/MS PerkinElmer NeoGram Kit 7 0.14 0.14 0.10 0.10 0.20
Derivatized - MS/MS non-kit 13 0.09 0.10 0.10 0.04 0.18
Non-derivatized - MS/MS PerkinElmer NeoBase Kit 18 0.09 0.10 0.10 0.04 0.16
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PT ERRORS
Screening programs are designed to minimize false 
negative reports, but this precautionary approach could 
result in false positive misclassifications. Laboratories 
should monitor false positive misclassifications to keep 
them as low as possible.
Tables 10 and 11 show the PT errors reported in 2015 by 
domestic and foreign laboratories for qualitative assess-
ments by disorder/analyte. Because of specific clinical 
assessment practices, presumptive clinical classifications 
(qualitative assessments) of some specimens might 
differ by participant. As stated previously, if participants 
provided their cutoff values, those cutoffs were applied 












Positive Errors  
(%)
Congenital Adrenal Hyperplasia 129 0.0 511 0.4
Biotinidase Deficiency 170 0.0 470 0.0
GALT Deficiency 214 0.5 426 0.0
G6PD Deficiency 2 0.0 6 0.0
Immunoreactive Trypsinogen 260 0.0 390 0.0
Congenital Hypothyroidism 264 0.0 731 0.0
Galactosemia 47 0.0 308 0.0
Arginine Screen 113 0.0 452 0.0
Citrulline Screen 138 0.0 552 0.0
Leucine Screen 140 0.0 560 0.5
Methionine Screen 138 0.0 552 0.0
Phenylalanine Screen 175 0.6 700 0.0
Succinylacetone Screen 91 0.0 364 0.0
Tyrosine Screen 162 1.2 648 0.0
Valine Screen 98 0.0 392 0.0
C0(L) Screen 146 1.4 584 0.0
C3  Screen 149 0.0 596 0.0
C3DC  Screen 65 0.0 260 0.0
C3DC+C4OH  Screen 120 1.7 180 0.0
C4 Screen 136 5.2 544 0.0
C4OH  Screen    63 1.6 252 1.2
C5 Screen 149 0.7 596 0.2
C5:1 Screen 146 4.1 584 0.0
C5OH Screen 146 0.0 584 1.2
C6 Screen 140 3.6 560 0.0
C8 Screen 149 0.0 596 0.0
C10  Screen 137 0.0 548 0.0
C10:1  Screen 131 0.0 524 0.0
C10:2  Screen 87 1.2 348 0.0
C14  Screen 138 4.4 552 0.0
C16 Screen 140 1.4 560 0.2
C18 Screen 128 0.0 512 0.0
C5DC Screen     146 0.0 584 0.0
C14:1  Screen 149 1.3 596 0.2
C16OH Screen 198 0.0 547 0.0
C18:1 Screen 131 0.0 524 0.0
C18OH Screen 115 1.7 460 0.0
XALD screen 8 0.0 12 0.0
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in the final evaluation of the error judgment. (Figure 4). 
The rates for false positive misclassifications are based 
on the number of negative specimens tested, and the 
rates for false negative misclassifications on the number 
of positive specimens tested. 
A few of our PT specimens fall close to the decision level 
for clinical assessment, and thus, rigorously tested the 
ability of laboratories to make the expected cutoff deci-
sion. Most specimens near the mean cutoff value are 
classified as not-evaluated specimens. As such, they are 
not included in the error calculations. 












Positive  Errors  
(%)
Congenital Adrenal Hyperplasia 517 1.0 2093 1.1
Biotinidase Deficiency 453 0.9 1257 0.6
GALT Deficiency 343 0.9 682 0.2
G6PD Deficiency 30 3.3 90 1.1
Immunoreactive Trypsinogen 818 1.7 1227 0.3
Congenital Hypothyroidism 1142 0.6 3133 0.8
Galactosemia 246 0.4 1574 0.4
Arginine Screen 555 2.0 2220 0.8
Citrulline Screen 606 0.8 2424 0.6
Leucine Screen 674 0.9 2696 0.3
Methionine Screen 656 1.8 2624 0.8
Phenylalanine Screen 916 0.7 3664 1.5
Succinylacetone Screen 221 1.8 884 0.9
Tyrosine Screen 670 1.2 2680 0.4
Valine Screen 619 1.0 2476 0.5
C0(L) Screen 675 4.9 2700 1.2
C3  Screen 654 1.7 2616 0.9
C3DC  Screen 308 1.3 1232 1.8
C3DC+C4OH  Screen 422 5.7 633 1.3
C4 Screen 612 2.6 2448 0.9
C4OH  Screen    282 3.9 1128 2.0
C5 Screen 680 1.3 2720 0.7
C5OH Screen 594 0.5 2376 3.8
C5:1 Screen 596 2.5 2384 1.0
C5DC Screen     664 1.4 2656 0.9
C6 Screen 632 1.4 2528 1.0
C8 Screen 692 1.0 2768 0.8
C10  Screen 665 1.5 2660 0.5
C10:1  Screen 594 2.7 2376 2.0
C10:2  Screen 404 2.0 1616 0.6
C14  Screen 623 2.1 2492 1.2
C14:1  Screen 652 1.7 2608 0.9
C16 Screen 657 2.0 2628 0.4
C16OH Screen 868 3.9 2387 1.1
C18 Screen 616 0.7 2464 0.7
C18:1 Screen 587 3.9 2348 0.9
C18OH Screen 504 3.0 2016 1.3
XALD Screen 4 0.0 6 0.0
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SICKLE CELL DISEASE AND OTHER HEMOGLOBINOPATHIES PT PROGRAM
Table 12 show the summary of PT errors for the 2015 
Sickle Cell and Hemoglobinopathy program by domestic 
and foreign laboratories. Table 13 shows the challenges 
distributed in 2015 for the sickle cell disease and other 
hemoglobinopathies and Table 14 shows the methods 
used by laboratories testing for them. Participants are 
evaluated on hemoglobin  presumptive phenotypes 
and ability to provide correct presumptive clinical 
assessments. 
Table 12: Summary of Proficiency Testing Errors for Hemoglobinopathies by Domestic and Foreign Laboratories in 2015 
Testing Errors Domestic Foreign
Specimens assayed 725 350
Presumptive phenotype errors 2.6% 3.4%
Presumptive clinical assessment errors 0.7% 1.2%
Table 13. 2015 Hemoglobinopathies Accepted Presumptive Phenotype Distribution
Panel Specimen 1 Specimen 2 Specimen 3 Specimen 4 Specimen 5
Panel 1 FA FAS FAE 
FAV
FAC for IEF only labs
FA + Other
FA FA
Panel 2 FAC FAS FA FA FAS
Panel 3 FAE or FAV FA FAC FA FAS





















Primary 38 27 5 0 0 0 0
Secondary 7 23 4 3 1 1 0
Tertiary 2 1 0 0 0 0 2
Quaternary 1 0 0 0 0 0 0
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CYSTIC FIBROSIS DNA MUTATION PT PROGRAM
Table 15 shows the PT errors for the CFDNA program. 
This program provides evaluations based on the allele 
identification and clinical assessment. Allele detection 
is dependent on the method used. Table 16 summarizes 
the CF mutation challenges distributed in 2015. 
TABLE 15. Summary of Proficiency Testing Errors for Cystic Fibrosis DNA Mutation Detection Specimens Distributed in 2015
















Q1, 2015 310 8 98.7% 1.3% 2.9% 3.1%
Q2, 2015 310 3 99.4% 0.6% 0.3% 4.6%
Q3, 2015 310 6 99.0% 1.0% 0.0% 7.5%
Q4, 2015 315 2 99.4% 0.6% 0.0% 6.0%
Total 1245 19 99.1% 0.9% 0.8% 5.3%
*This includes specimens where the PCR failed or participant failed to include a clinical assessment. 
TABLE 16.  Cystic Fibrosis DNA Mutation (CFTR gene) Challenges Distributed in 2015 
Mutation (Legacy Name) Mutation (HGVS Nomenclature) Mutations sent
F508del c.1521_1523delCTT 13










G551D c.1652G>A 1 
R117H c.350G>A 1
621+1G>T c.489+1G>T 1
S492F c. 1475C>T 1
Note: Five specimens are sent each of the four quarters and each sample has two mutations or wild type sequences.
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PT BIAS PLOTS
Figures 5 – 40 are illustrated for PT analytes reported 
using the NSQAP data reporting website. A wide range 
of quantitatively measured PT challenges are selected 
for the bias plots. Comparisons of results by different 
methods are illustrated with the participants’ reported 
PT data for one selected challenge for each analyte.
The expected value of each specimen equals the sum of 
the enriched value and the endogenous (non-enriched) 
value. GALT, G6PD, and C0(L) use CDC-assayed values 
due to production methods for deficient analytes. IRT 
standard cannot be fully recovered by any IRT analytical 
method; therefore, IRT PT uses CDC-assayed values. 
A growing number of NSQAP participants use a non-
derivatized MS/MS method for amino acids and acyl-
carnitine analysis. However, non-derivatized MS/MS 
methods cannot distinguish between analytes C3DC 
and C4OH (i.e., they are isobaric). Laboratories using a 
non-derivatized MS/MS method report C3DC+C4OH, 
while derivatized MS/MS method users continue to 
report those analytes separately.
These bias plots show the difference of the reported 
value (positive or negative) by laboratory and method 
subtracted from the expected or assayed value. To 
illustrate method-related differences in analyte recov-
eries, the PT quantitative results are grouped by kit or 
method. 
For each plot, note the scale-changes of the Y-axis. A re-
ported value matching the expected value falls on the 
plot’s “0” line. For each figure, a summary of the speci-
men data for the selected PT challenge is tabulated in 
the left margin. Ideally, a reasonable bias is less than 
20% of the expected value (EV). 
The bias plots (Figures 5-40)  illustrate the 95% CI  
for the participant mean. A tight scatter within this 
interval indicates good performance for a method or a 
group of methods. In general, the quantitative compari-
sons for PT challenges are reasonable within a method 
but vary among methods. Because some of the pools 
in a routine PT survey represent a unique donor speci-
men, differences in endogenous concentration levels  
in the donor specimens might influence differences  
in methods.
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Figure 4. EXPLANATION OF THE NEWBORN SCREENING 
QUALITY ASSURANCE PROGRAM’S GRADING ALGORITHM
Part 1
The NSQAP Expected Clinical Assessment for PT speci-
mens is determined by comparing the NSQAP Expected 
Certified Value and the NSQAP Cutoff. The NSQAP Certi-
fied Expected Value is the sum of the endogenous val-
ue plus the enrichment value for an individual analyte. 
The enrichments for each PT specimen are calculated so 
that the 95% confidence interval falls above or below 
the NSQAP cutoff value. The NSQAP Cutoff Value is 
determined annually by using the mean of all domestic 
laboratories’ reported cutoff values as a guideline. 
Part 2
The participant reports the clinical assessment as 
“within normal limits” or “outside normal limits.” This is 
the Participant Reported Clinical Assessment. The 
Participant Expected Clinical Assessment is the as-
sessment that is expected when the NSQAP Certified 
Expected Value and the participant cutoff are compared. 
When the Participant Reported Clinical Assessment dif-
fers from the NSQAP Expected Clinical Assessment, the 
grading algorithm is used to evaluate test performance. 
The algorithm will determine if the Participant Reported 
Clinical Assessment is correct, false negative, false posi-
tive or cutoff difference. 
• If the NSQAP Expected Clinical Assessment is the
same as the Participant Expected Clinical Assessment
but the Participant Reported Assessment differs, the
grade will be either false negative or false positive.
• If the NSQAP Expected Clinical Assessment and the
Participant Expected Clinical Assessment differ, the
Participant Reported clinical assessment will not be
graded as incorrect. (If a cutoff is not provided by
the participant, the evaluation will be based on the
NSQAP Cutoff Value)
Part 3
Determination of a final evaluation for a specimen is 
based on the Clinical Laboratory Improvement Amend-
ments (CLIA) regulations whereby the PT provider “must 
compare the laboratory’s response for each analyte with 
the response that reflects agreement of either 80% of 
ten or more referee laboratories or 80% or more of all 
participating laboratories.” (CLIA Regulations, 2004). 
An NSQAP gradable specimen must have 80% or more 
agreement among domestic laboratories. A specimen 
with less than 80% agreement is not-gradable/not-
evaluated. 
Example of TSH false positive –
NSQAP Certified Expected Value = 13 µIU/mL 
NSQAP Cutoff = 30 µIU/mL
Participant cutoff = 35 µIU/mL 
Participant’s Reported Clinical Assessment = 
2- Outside Normal Limits for this sample.
1. Comparison of the NSQAP Certified Expected
Value and NSQAP Cutoff:
NSQAP Certified Expected Value = 13 µIU/mL 
NSQAP Cutoff = 30 µIU/mL 
Therefore, the NSQAP Expected Clinical 
Assessment = 1- Within Normal Limits
2.  Comparison of the NSQAP Certified Expected
Value and Participant Cutoff
NSQAP Certified Expected Value = 13 µIU/mL 
Participant Cutoff = 35 µIU/mL 
Therefore the Participant Expected Clinical Assess-
ment = 1- Within Normal Limits
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3. Participant Reported Clinical Assessment
= 2-Outside Normal Limits
In this example, the NSQAP Expected  
Clinical Assessment and the Participant  
Expected Clinical Assessment were both  
“1- Within Normal Limits” but the Participant 
Reported Clinical Assessment is  
“2- Outside Normal Limits” therefore: 
Participant Evaluation Result = false positive























TSH 13 30 35 wnl wnl onl false 
positive
TSH 13 30 10 wnl onl onl cutoff 
difference
TSH 50 30 35 onl onl wnl false 
negative
TSH 50 30 60 onl wnl wnl cutoff 
difference
wnl- “1- Within Normal Limits” 
onl -“2- Outside Normal limits”
Reference: CLIA Regulations Subpart I—Proficiency Testing Programs for Nonwaived Testing. [Updated 2004 July 7; 
accessed 2014 January 31]. Available from http://wwwn.cdc.gov/clia/regs/subpart_i.aspx#493.931
Grading is based on the participant reported clinical assessment, not on the reported value. Overall statistics, which  
are generated from all participant data, and mean reported concentrations by method are provided on the website for  
analytical reference only.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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FIGURES 9-10. Reproducibility of Results by Method: Galactose-1-phosphate Uridyltransferase (GALT) 











1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
June  201626













1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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1EV is the sum of the endogenous and enrichment values.  The solid line represents perfect agreement with the EV or zero bias.
2Participant bias (X) is the mean value of all participants’ assayed values minus EV; represented by the broken line. Participant bias (X) excludes outlier values. 
    The 95% confidence interval is shown.
3AV is the CDC assayed value.  The solid line represents perfect agreement with the AV or zero bias.
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QUALITY CONTROL
The QC program helps laboratories maintain high levels 
of technical proficiency and continuity, particularly dur-
ing lot-to-lot changes in commercial assay systems or 
reagents. The QC materials, which supplement the par-
ticipants’ method- or kit-control materials, allow partici-
pants to monitor long-term assay stability. QC materials 
are distributed semiannually. 
QC MATERIALS AND METHODS
NSQAP certifies QC analysis materials for homogeneity, 
accuracy, stability, and suitability for newborn screen-
ing assays. We distribute QC analysis materials (DBS 
cards), instructions for storage, analysis, and certifica-
tion sheets in each shipment. Download QC certifica-
tion sheets and data report forms from our website at: 
http://www.cdc.gov/labstandards/nsqap_resources.
html
QC materials are produced by combining blood from 
multiple donors. The RBCs are washed several times, 
combined with purified serum to achieve a 50% he-
matocrit, and then lysed. Each lot within a set of QC 
shipments contains a different analyte concentration 
of the following:  T
4
, TSH, 17OHP, IRT, TGal, GALT, amino 
acids (alanine, Arg, Cit, Leu, Met, Phe, SUAC, Tyr, Val), and 
acylcarnitines (C0, C2, C3, C3DC, C4, C4OH, C5, C5DC, 
C5OH, C6, C8, C10, C12, C14, C16, C16OH, C18, C18OH), 
and XALD.
• Purified analyte standards are used for most QC 
material enrichments, with the exception of TSH, for 
which the Third International Reference Preparation 
(81/565) is used. 
• T
4





 depletion of the base serum. 
• TGal materials are enriched with galactose and 
galactose-1-phosphate, allowing measurement 
of both free galactose (galactose alone) and total 
galactose (free galactose plus galactose present as 
TGal). 
• GALT QC materials are made using a 50/50 saline/
serum solution combined with compatible washed 
RBCs and then heat-treating the pool.
To ensure laboratories receive representative sheets of 
QC materials from each lot, we use a system to random-
ize blood spot cards from across the production batch. 
QC DATA HANDLING
For each semiannual QC event, data points from five 
independent runs of each QC analyte lot level are com-
piled and tabulated. 
Tables 17a–17jj show the reported QC data. The tables 
show the analyte by series of QC lots, number of mea-
surements (N), mean values, within-laboratory standard 
deviations (SD), and total SDs by kit or analytic method. 
In addition, we use a weighted linear-regression analysis 
to examine the comparability by method of reported 
versus enriched concentrations. We calculate linear re-
gressions (Y-intercept and slope) by method for all ana-
lytic values within an analyte QC series. Values outside 
the 99% CI (outliers) are excluded from the calculations. 
Tables 17a–17jj show data for method-related differ-
ences in analytic recoveries and method biases. For 
regression analyses, we calculated the within-laboratory 
SD component of the total SD and used the reported 
QC data from multiple analytic runs. We calculated the 
Y-intercept and slope in each table, using all analyte 
concentrations within a lot series (e.g., lots 1425, 1426, 
1427, 1428). Because only three or four concentrations 
of QC materials are available for each analyte, a bias 
in any one pool can markedly influence the slope and 
intercept. The Y-intercept provides one measure of the 
endogenous concentration level for an analyte. For 
amino acids and acylcarnitines, participants measure 
the endogenous concentrations by analyzing the non-
enriched QC lots; for most methods, the Y-intercepts 
and measured endogenous levels were similar. Ideally, 
the slope should be 1.0. Slope deviations might relate to 
analytic (dose-response) ranges for calibration curves or 
to poor recoveries for one or more specimens in a three- 
or four-specimen QC set. Because the endogenous con-
centration is the same for all QC lots within a series, it 
should not affect the slope of the regression line among 
methods. Generally, slope values substantially different 
from 1.0 indicate that a method has an analytic bias. 
In certain circumstances, where no unit conversion fac-
tor exists to allow for direct comparison of enrichment 
values to observed concentrations, we provide basic 
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Table 17a. 2015 Quality Control Data Summaries of Statistical Analyses 
17 α-HYDROXYPROGESTERONE (ng 17OHP/mL serum) 
Lot 1351 - Enriched 25.0 ng/mL serum 
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 30 21.9 1.7 3.5 5.9 0.7
Neo-Genesis Accuwell 30 23.5 3.0 5.7 -2.0 1.0
Delfia 140 19.0 2.4 5.1 -2.2 0.9
Delfia Neonatal 17-OHP (A024) 89 17.9 2.3 3.3 -2.4 0.8
AutoDelfia 262 20.4 2.4 3.8 -0.2 0.9
AutoDelfia Neonatal 17-OHP (B024) 345 20.5 2.1 3.0 0.5 0.8
Bio-Rad Quantase 90 21.4 2.9 5.3 3.0 0.8
TecnoSuma UMELISA 20 23.8 2.6 2.7 -5.6 1.2
LC-MS/MS 39 21.8 1.9 3.5 1.0 0.8
PerkinElmer GSP Neonatal 320 21.4 1.9 2.3 1.6 0.8
In House 20 24.1 6.3 6.3 2.8 0.8
Lot 1352 - Enriched 50.0 ng/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 30 43.0 3.0 7.0 5.9 0.7
Neo-Genesis Accuwell 29 47.0 6.1 6.4 -2.0 1.0
Delfia 140 40.6 3.7 8.7 -2.2 0.9
Delfia Neonatal 17-OHP (A024) 89 38.8 4.8 7.2 -2.4 0.8
AutoDelfia 263 44.7 3.9 8.4 -0.2 0.9
AutoDelfia Neonatal 17-OHP (B024) 345 43.0 3.8 6.1 0.5 0.8
Bio-Rad Quantase 90 47.7 4.9 15.6 3.0 0.8
TecnoSuma UMELISA 20 57.0 6.6 12.0 -5.6 1.2
LC-MS/MS 40 43.2 3.8 5.9 1.0 0.8
PerkinElmer GSP Neonatal 324 44.1 3.3 4.5 1.6 0.8
In House 20 42.1 4.9 9.3 2.8 0.8
Lot 1353 - Enriched 100.0 ng/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 30 75.0 4.9 13.7 5.9 0.7
Neo-Genesis Accuwell 30 97.9 16.2 19.8 -2.0 1.0
Delfia 144 83.0 9.3 23.9 -2.2 0.9
Delfia Neonatal 17-OHP (A024) 90 79.3 11.3 18.1 -2.4 0.8
AutoDelfia 252 85.9 8.9 15.1 -0.2 0.9
AutoDelfia Neonatal 17-OHP (B024) 341 83.0 8.6 12.5 0.5 0.8
Bio-Rad Quantase 78 84.5 8.9 18.9 3.0 0.8
TecnoSuma UMELISA 20 115.6 7.7 18.3 -5.6 1.2
LC-MS/MS 40 84.7 4.8 9.9 1.0 0.8
PerkinElmer GSP Neonatal 319 83.8 7.2 8.9 1.6 0.8
In House 20 84.6 6.2 23.3 2.8 0.8
 
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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17 α-HYDROXYPROGESTERONE (ng 17OHP/mL serum)
Lot 1551 - Enriched 25.0 ng/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 30 29.6 2.4 3.6 5.8 1.0
Neo-Genesis Accuwell 30 26.6 2.8 3.1 -2.6 1.1
Delfia 217 22.8 2.4 4.4 -0.6 0.9
Delfia Neonatal 17-OHP (A024) 80 22.7 2.9 5.0 -0.4 0.9
AutoDelfia 217 23.8 2.0 2.7 -0.7 1.0
AutoDelfia Neonatal 17-OHP (B024) 368 23.8 2.4 4.3 -1.3 1.0
Bio-Rad Quantase 77 22.5 3.2 7.7 1.5 0.9
TecnoSuma UMELISA 10 26.5 1.3 1.3 1.7 1.0
LC-MS/MS 60 24.8 2.8 6.5 2.9 0.9
PerkinElmer GSP Neonatal 351 25.0 2.0 2.8 0.4 1.0
In House 19 28.6 3.6 3.6 7.4 0.9
Lot 1552 - Enriched 50.0 ng/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 30 54.4 4.0 8.7 5.8 1.0
Neo-Genesis Accuwell 30 48.4 4.7 6.5 -2.6 1.1
Delfia 214 44.4 4.6 7.3 -0.6 0.9
Delfia Neonatal 17-OHP (A024) 76 44.1 4.6 10.0 -0.4 0.9
AutoDelfia 213 46.6 4.1 4.8 -0.7 1.0
AutoDelfia Neonatal 17-OHP (B024) 361 46.8 4.0 7.9 -1.3 1.0
Bio-Rad Quantase 78 45.7 6.2 17.3 1.5 0.9
TecnoSuma UMELISA 10 49.7 3.7 3.7 1.7 1.0
LC-MS/MS 60 47.4 4.0 11.5 2.9 0.9
PerkinElmer GSP Neonatal 347 47.9 3.5 4.2 0.4 1.0
In House 18 54.5 3.8 4.9 7.4 0.9
Lot 1553 - Enriched 100.0 ng/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 30 102.0 8.4 16.6 5.8 1.0
Neo-Genesis Accuwell 30 106.9 11.1 13.6 -2.6 1.1
Delfia 217 91.2 10.0 15.9 -0.6 0.9
Delfia Neonatal 17-OHP (A024) 75 90.4 9.9 19.6 -0.4 0.9
AutoDelfia 222 95.5 9.2 12.9 -0.7 1.0
AutoDelfia Neonatal 17-OHP (B024) 367 97.0 9.7 18.2 -1.3 1.0
Bio-Rad Quantase 77 87.7 15.7 35.0 1.5 0.9
TecnoSuma UMELISA 10 99.3 9.3 9.3 1.7 1.0
LC-MS/MS 60 91.3 5.6 23.8 2.9 0.9
PerkinElmer GSP Neonatal 349 96.9 7.9 11.6 0.4 1.0
In House 20 96.8 7.2 28.9 7.4 0.9
 *Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17b. 2015 Quality Control Data Summaries of Statistical Analyses 
THYROID-STIMULATING HORMONE (μIU TSH/mL serum)
Lot 1411 - Enriched 25.0 μIU/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 20 35.4 4.2 5.1 -1.0 1.4
Neo-Genesis Accuwell 40 25.2 4.3 4.9 -0.4 1.1
MP Biomedicals ELISA 20 15.9 2.2 4.1 -6.6 0.9
Delfia 427 26.3 2.8 5.3 -0.7 1.1
AutoDelfia 862 28.0 2.5 4.5 -0.2 1.1
Ani Labsystems 89 25.6 2.2 3.7 -5.1 1.2
Bio-Rad Quantase 70 32.8 4.0 11.8 1.3 1.3
TecnoSuma UMELISA 29 32.9 4.0 4.5 -2.5 1.4
Bioclone ELISA 10 25.7 0.9 0.9 -0.3 1.1
DiaSorin 88 25.0 2.1 3.0 1.5 1.0
Interscientific NeoMAP Multiplex 50 24.6 1.7 2.3 -3.0 1.1
PerkinElmer GSP Neonatal 431 26.7 2.2 2.9 0.0 1.1
In House 40 25.7 1.8 2.7 1.1 1.0
Lot 1412 - Enriched 40.0 μIU/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 20 55.7 5.0 7.0 -1.0 1.4
Neo-Genesis Accuwell 40 42.7 4.8 7.3 -0.4 1.1
MP Biomedicals ELISA 20 26.6 3.2 7.6 -6.6 0.9
Delfia 427 44.0 4.8 8.1 -0.7 1.1
AutoDelfia 841 45.9 3.5 5.0 -0.2 1.1
Ani Labsystems 88 43.4 4.1 6.2 -5.1 1.2
Bio-Rad Quantase 70 54.2 5.5 21.8 1.3 1.3
TecnoSuma UMELISA 28 53.4 4.4 5.1 -2.5 1.4
Bioclone ELISA 10 43.6 2.2 2.2 -0.3 1.1
DiaSorin 90 40.0 3.6 6.6 1.5 1.0
Interscientific NeoMAP Multiplex 50 41.7 2.5 3.2 -3.0 1.1
PerkinElmer GSP Neonatal 433 42.7 3.2 4.5 0.0 1.1
In House 40 41.3 3.1 5.2 1.1 1.0
Lot 1413 - Enriched 80.0 μIU/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 20 114.0 11.5 11.9 -1.0 1.4
Neo-Genesis Accuwell 39 83.5 9.7 10.9 -0.4 1.1
MP Biomedicals ELISA 20 62.7 8.0 19.2 -6.6 0.9
Delfia 412 87.1 7.8 15.4 -0.7 1.1
AutoDelfia 838 91.0 7.1 10.0 -0.2 1.1
Ani Labsystems 88 92.6 6.3 12.6 -5.1 1.2
Bio-Rad Quantase 70 104.5 11.5 47.6 1.3 1.3
TecnoSuma UMELISA 29 110.0 7.0 7.0 -2.5 1.4
Bioclone ELISA 10 85.0 2.9 2.9 -0.3 1.1
DiaSorin 89 77.6 5.3 11.2 1.5 1.0
Interscientific NeoMAP Multiplex 48 85.9 5.1 6.4 -3.0 1.1
PerkinElmer GSP Neonatal 435 85.5 6.6 9.2 0.0 1.1
In House 40 80.7 5.2 15.4 1.1 1.0
 *Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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THYROID-STIMULATING HORMONE (μIU TSH/mL serum)
Lot 1511 - Enriched 25.0 μIU/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 20 33.4 3.1 4.5 -0.5 1.4
Neo-Genesis Accuwell 39 26.9 2.8 4.1 -1.8 1.2
MP Biomedicals ELISA 20 20.5 1.8 4.0 -2.9 1.0
Delfia 415 27.8 2.5 3.6 -0.5 1.2
AutoDelfia 880 27.8 2.2 5.8 -1.2 1.2
Ani Labsystems 80 26.9 2.1 2.7 -1.9 1.2
Bio-Rad Quantase 70 23.7 2.1 9.0 0.8 0.9
TecnoSuma UMELISA 20 36.9 5.3 14.2 -6.0 1.8
Bioclone ELISA 20 17.9 1.4 11.2 1.2 0.7
DiaSorin 79 29.5 3.0 3.9 -1.8 1.3
Interscientific NeoMAP Multiplex 49 27.0 1.8 1.9 1.4 1.1
PerkinElmer GSP Neonatal 462 26.7 1.9 2.4 -2.7 1.2
In House 49 29.0 2.4 4.1 0.0 1.2
Lot 1512 - Enriched 40.0 μIU/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 20 59.3 4.5 6.6 -0.5 1.4
Neo-Genesis Accuwell 40 46.2 5.0 5.0 -1.8 1.2
MP Biomedicals ELISA 20 38.2 3.8 3.8 -2.9 1.0
Delfia 420 48.0 4.3 5.8 -0.5 1.2
AutoDelfia 865 48.1 3.5 9.8 -1.2 1.2
Ani Labsystems 76 48.7 3.5 3.6 -1.9 1.2
Bio-Rad Quantase 70 38.0 3.6 15.1 0.8 0.9
TecnoSuma UMELISA 20 67.3 10.1 23.5 -6.0 1.8
Bioclone ELISA 20 29.8 2.9 19.1 1.2 0.7
DiaSorin 76 54.0 5.4 6.6 -1.8 1.3
Interscientific NeoMAP Multiplex 49 48.9 3.3 3.6 1.4 1.1
PerkinElmer GSP Neonatal 464 47.2 3.1 4.9 -2.7 1.2
In House 49 46.5 3.0 4.3 0.0 1.2
Lot 1513 - Enriched 80.0 μIU/mL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 20 113.2 8.5 10.5 -0.5 1.4
Neo-Genesis Accuwell 40 92.0 7.3 7.4 -1.8 1.2
MP Biomedicals ELISA 20 75.5 13.2 15.7 -2.9 1.0
Delfia 418 93.2 8.9 11.9 -0.5 1.2
AutoDelfia 877 94.3 6.9 19.9 -1.2 1.2
Ani Labsystems 78 94.4 5.9 9.2 -1.9 1.2
Bio-Rad Quantase 70 74.7 9.3 32.9 0.8 0.9
TecnoSuma UMELISA 20 135.8 23.2 64.7 -6.0 1.8
Bioclone ELISA 20 56.5 5.3 37.7 1.2 0.7
DiaSorin 74 103.5 9.1 10.1 -1.8 1.3
Interscientific NeoMAP Multiplex 49 89.5 7.2 8.0 1.4 1.1
PerkinElmer GSP Neonatal 465 94.1 6.5 8.7 -2.7 1.2
In House 50 92.7 7.1 13.5 0.0 1.2
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis
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Lot 1401 - Enriched 2.0 μg/dL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Neo-Genesis Accuwell 37 1.3 0.2 0.2 -0.3 0.9
Delfia 175 1.8 0.3 0.4 -0.2 1.0
AutoDelfia 411 1.9 0.3 0.3 -0.1 1.0
Interscientific NeoMAP Multiplex 99 1.8 0.3 0.3 -0.2 1.0
PerkinElmer GSP Neonatal 374 1.8 0.2 0.2 -0.3 1.0
Lot 1402 - Enriched 7.0 μg/dL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Neo-Genesis Accuwell 40 6.4 1.0 2.1 -0.3 0.9
Delfia 176 6.5 0.7 0.9 -0.2 1.0
AutoDelfia 420 6.6 0.6 0.7 -0.1 1.0
Interscientific NeoMAP Multiplex 99 6.3 0.5 0.5 -0.2 1.0
PerkinElmer GSP Neonatal 380 6.8 0.7 0.7 -0.3 1.0
Lot 1403 - Enriched 11.0 μg/dL serum
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Neo-Genesis Accuwell 40 9.2 0.9 1.8 -0.3 0.9
Delfia 174 10.6 0.9 1.5 -0.2 1.0
AutoDelfia 420 10.6 1.0 1.1 -0.1 1.0
Interscientific NeoMAP Multiplex 100 10.5 0.9 0.9 -0.2 1.0
PerkinElmer GSP Neonatal 368 11.2 1.2 1.3 -0.3 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17d. 2015 Quality Control Data Summaries of Statistical Analyses 
TOTAL GALACTOSE (mg TGal/dL blood)
Lot 1425 - Enriched 5.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 5.6 0.5 0.6 1.4 0.9
Fluorometric Manual 99 4.6 0.5 1.3 0.8 0.9
Colorimetric 64 6.3 0.9 1.5 1.3 1.1
PerkinElmer Neonatal Kit 255 5.2 0.6 1.0 1.4 0.8
Neo-Genesis Accuwell 29 6.6 0.5 1.4 0.6 1.2
Bio-Rad Quantase 129 6.8 1.2 1.7 -0.9 1.4
Interscientific Enzyme 30 5.3 0.4 0.5 1.2 0.8
Astoria-Pacific 50 Hour Reagent Kit 97 6.7 0.5 0.7 1.6 1.0
TecnoSuma UMTEST 30 8.2 1.7 2.1 2.5 1.1
Lot 1426 - Enriched 10.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 11.0 0.6 0.6 1.4 0.9
Fluorometric Manual 96 9.4 0.7 2.0 0.8 0.9
Colorimetric 68 12.7 1.3 2.4 1.3 1.1
PerkinElmer Neonatal Kit 257 9.5 0.9 1.4 1.4 0.8
Neo-Genesis Accuwell 29 13.1 1.0 2.1 0.6 1.2
Bio-Rad Quantase 128 12.7 2.0 2.8 -0.9 1.4
Interscientific Enzyme 30 9.1 1.0 1.0 1.2 0.8
Astoria-Pacific 50 Hour Reagent Kit 100 11.9 0.8 1.2 1.6 1.0
TecnoSuma UMTEST 30 12.6 1.4 3.0 2.5 1.1
Lot 1427 - Enriched 15.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 15.5 1.0 1.2 1.4 0.9
Fluorometric Manual 90 15.4 1.2 1.2 0.8 0.9
Colorimetric 70 18.2 2.0 3.6 1.3 1.1
PerkinElmer Neonatal Kit 257 13.6 1.3 2.1 1.4 0.8
Neo-Genesis Accuwell 30 18.3 1.3 2.4 0.6 1.2
Bio-Rad Quantase 130 19.3 2.3 4.4 -0.9 1.4
Interscientific Enzyme 30 13.8 1.1 1.3 1.2 0.8
Astoria-Pacific 50 Hour Reagent Kit 99 16.9 1.1 2.1 1.6 1.0
TecnoSuma UMTEST 30 20.2 1.9 3.1 2.5 1.1
Lot 1428 - Enriched 30.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 29.0 2.1 10.1 1.4 0.9
Fluorometric Manual 100 26.9 1.8 6.4 0.8 0.9
Colorimetric 70 34.2 3.6 8.6 1.3 1.1
PerkinElmer Neonatal Kit 266 25.2 2.3 3.6 1.4 0.8
Neo-Genesis Accuwell 28 37.1 2.3 2.9 0.6 1.2
Bio-Rad Quantase 140 41.2 5.3 10.2 -0.9 1.4
Interscientific Enzyme 30 25.5 2.2 2.5 1.2 0.8
Astoria-Pacific 50 Hour Reagent Kit 100 32.2 1.9 3.6 1.6 1.0
TecnoSuma UMTEST 30 35.5 2.8 6.1 2.5 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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TOTAL GALACTOSE (mg TGal/dL blood)
Lot 1521 - Enriched 5.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 5.4 0.4 0.5 1.6 0.8
Fluorometric Manual 99 5.1 0.7 1.2 0.4 1.0
Colorimetric 57 5.9 0.8 1.2 0.2 1.1
PerkinElmer Neonatal Kit 259 5.3 0.7 1.1 1.2 0.8
Neo-Genesis Accuwell 28 6.4 0.6 1.1 0.7 1.2
Bio-Rad Quantase 153 6.5 0.7 1.4 0.5 1.1
Interscientific Enzyme 39 6.1 0.6 0.7 1.7 0.8
PerkinElmer GSP Neonatal 105 5.5 0.4 0.7 1.0 0.9
Astoria-Pacific 50 Hour Reagent Kit 87 6.6 0.5 0.9 1.7 0.9
TecnoSuma UMTEST 18 7.7 0.4 0.4 1.7 1.1
Lot 1522 - Enriched 10.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 9.7 0.6 0.8 1.6 0.8
Fluorometric Manual 90 10.0 0.7 1.5 0.4 1.0
Colorimetric 60 11.3 1.4 2.9 0.2 1.1
PerkinElmer Neonatal Kit 263 8.9 1.0 1.6 1.2 0.8
Neo-Genesis Accuwell 30 12.9 1.1 3.2 0.7 1.2
Bio-Rad Quantase 149 11.0 1.3 2.2 0.5 1.1
Interscientific Enzyme 39 9.6 0.8 1.3 1.7 0.8
PerkinElmer GSP Neonatal 110 9.9 1.0 1.3 1.0 0.9
Astoria-Pacific 50 Hour Reagent Kit 90 10.9 0.8 1.3 1.7 0.9
TecnoSuma UMTEST 20 12.5 1.3 1.7 1.7 1.1
Lot 1523 - Enriched 15.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 13.9 0.9 1.2 1.6 0.8
Fluorometric Manual 90 15.0 1.2 1.8 0.4 1.0
Colorimetric 60 16.7 2.0 4.4 0.2 1.1
PerkinElmer Neonatal Kit 264 12.9 1.1 2.1 1.2 0.8
Neo-Genesis Accuwell 28 18.0 1.1 2.7 0.7 1.2
Bio-Rad Quantase 147 15.9 1.6 3.0 0.5 1.1
Interscientific Enzyme 40 13.8 0.8 2.4 1.7 0.8
PerkinElmer GSP Neonatal 108 13.7 1.2 1.5 1.0 0.9
Astoria-Pacific 50 Hour Reagent Kit 89 15.1 0.9 1.3 1.7 0.9
TecnoSuma UMTEST 20 18.8 1.9 4.1 1.7 1.1
Lot 1524 - Enriched 30.0 mg/dL blood
METHOD N Mean Average Within Lab SD Total SD Y- Intercept* Slope
Siemens Healthcare Diagnostics 40 25.5 1.3 5.9 1.6 0.8
Fluorometric Manual 94 29.0 2.5 3.6 0.4 1.0
Colorimetric 60 33.5 3.3 10.0 0.2 1.1
PerkinElmer Neonatal Kit 261 24.7 2.0 3.5 1.2 0.8
Neo-Genesis Accuwell 30 35.9 2.9 6.2 0.7 1.2
Bio-Rad Quantase 151 33.0 3.1 7.2 0.5 1.1
Interscientific Enzyme 39 26.4 2.3 4.4 1.7 0.8
PerkinElmer GSP Neonatal 107 27.5 2.7 3.2 1.0 0.9
Astoria-Pacific 50 Hour Reagent Kit 88 29.5 1.5 3.1 1.7 0.9
TecnoSuma UMTEST 20 35.6 3.6 7.9 1.7 1.1
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Table 17e. 2015 Quality Control Data Summaries of Statistical Analyses 
GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE (U GALT/g Hb)




Lab SD Total SD Y- Intercept* Slope
PerkinElmer Neonatal Kit 295 1.3 0.3 0.5 0.2 0.7
Astoria-Pacific Neonatal  Microplate Reagent Kit 40 0.6 0.1 0.2 -0.6 0.7




Lab SD Total SD Y- Intercept* Slope
PerkinElmer Neonatal Kit 293 3.0 0.4 0.5 0.2 0.7
Astoria-Pacific Neonatal Microplate Reagent Kit 39 2.1 0.2 0.3 -0.6 0.7




Lab SD Total SD Y- Intercept* Slope
PerkinElmer Neonatal Kit 295 7.2 0.9 1.2 0.2 0.7
Astoria-Pacific Neonatal Microplate Reagent Kit 40 6.6 0.7 1.0 -0.6 0.7
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
Methods Reported in Units Other Than U/g Hb (>3 Participants)*
Lot  












Astoria-Pacific 50 Hour Reagent Kit 
(µmol/L blood)
70 14.7 1.9 3.9 8.1 23.2
Perkin Elmer GSP Neonatal  
(U/dL blood)
70 0.5 0.2 1.0 0.0 2.5
1432
Astoria-Pacific 50 Hour Reage nt Kit 
(µmol/L blood)
70 66.3 6.5 10.0 45.0 94.6
Perkin Elmer GSP Neonatal  
(U/dL blood)
70 1.5 0.3 0.6 0.5 2.5
1433
Astoria-Pacific 50 Hour Reagent Kit 
(µmol/L blood)
70 193.0 28.9 44.4 90.0 303.4
Perkin Elmer GSP Neonatal  
(U/dL blood)
70 8.2 0.7 1.3 5.3 10.2
 *Outlier data was removed based on the 99% confidence interval
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Table 17e. 2015 Quality Control Data Summaries of Statistical Analyses 
GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE (U GALT/g Hb)




Lab SD Total SD Y- Intercept* Slope
PerkinElmer Neonatal Kit 261 1.3 0.3 0.4 0.2 0.7
Astoria-Pacific Neonatal Microplate Reagent Kit 70 0.7 0.1 0.2 -0.4 0.7




Lab SD Total SD Y- Intercept* Slope
PerkinElmer Neonatal Kit 267 2.6 0.3 0.5 0.2 0.7
Astoria-Pacific Neonatal Microplate Reagent Kit 70 2.1 0.2 0.5 -0.4 0.7




Lab SD Total SD Y- Intercept* Slope
PerkinElmer Neonatal Kit 277 5.9 0.6 0.9 0.2 0.7
Astoria-Pacific Neonatal Microplate Reagent Kit 70 5.3 0.6 1.0 -0.4 0.7
Methods Reported in Units Other Than U/g Hb (>3 Participants)*
Lot  












Astoria-Pacific 50 Hour Reagent Kit 
(µmol/L blood)
60 16.9 2.6 3.1 10.0 24.7
Perkin Elmer GSP Neonatal  
(U/dL blood)
91 0.7 0.1 1.0 0.0 2.5
1532
Astoria-Pacific 50 Hour Reagent Kit 
(µmol/L blood)
60 63.8 8.5 13.4 36.0 87.3
Perkin Elmer GSP Neonatal  
(U/dL blood)
100 1.7 0.3 0.6 0.2 2.8
1533
Astoria-Pacific 50 Hour Reagent Kit 
(µmol/L blood)
60 171.3 25.2 53.6 52.0 266.9
Perkin Elmer GSP Neonatal  
(U/dL blood)
100 7.5 0.6 1.1 5.2 4.7
 *Outlier data was removed based on the 99% confidence interval
Several laboratories reported their GALT results in either µmol/L blood or U/dL blood according to their analytic method.NSQAP’s certified units for GALT are U/g 
hemoglobin. Due to the lack of a conversion factor between U/g hemoglobin and µmol/L blood or U/dL blood, the linear regression parameters cannot be calcu-
lated for these units of measure. Basic peer-group statistics are provided to assist in self-assessment under those circumstances.
June  201652
Table 17f. 2015 Quality Control Data Summaries of Statistical Analyses 
IMMUNOREACTIVE TRYPSINOGEN (ng IRT/mL blood)




Lab SD Total SD Y- Intercept* Slope
MP Biomedicals ELISA 89 24.3 3.0 8.1 29.7 1.1
Delfia 400 19.3 2.4 2.7 2.1 0.9
AutoDelfia 1410 19.5 1.7 2.0 2.0 1.0
Bio-Rad Quantase 40 50.4 5.0 21.7 58.2 0.9
PerkinElmer GSP Neonatal 647 19.6 1.4 1.5 0.4 1.0




Lab SD Total SD Y- Intercept* Slope
MP Biomedicals ELISA 83 114.7 14.3 32.7 29.7 1.1
Delfia 412 67.8 6.5 7.8 2.1 0.9
AutoDelfia 1399 70.2 5.6 6.7 2.0 1.0
Bio-Rad Quantase 40 138.0 5.2 49.2 58.2 0.9
PerkinElmer GSP Neonatal 664 71.6 4.3 4.5 0.4 1.0




 Lab SD Total SD Y- Intercept* Slope
MP Biomedicals ELISA 88 237.9 41.2 83.3 29.7 1.1
Delfia 406 140.2 13.9 15.8 2.1 0.9
AutoDelfia 1367 143.5 9.5 10.6 2.0 1.0
Bio-Rad Quantase 40 217.7 7.9 66.7 58.2 0.9
PerkinElmer GSP Neonatal 663 148.8 8.8 9.8 0.4 1.0




 Lab SD Total SD Y- Intercept* Slope
MP Biomedicals ELISA 65 281.5 40.7 98.1 29.7 1.1
Delfia 408 242.8 22.0 27.1 2.1 0.9
AutoDelfia 1390 249.7 18.1 20.4 2.0 1.0
Bio-Rad Quantase 40 275.3 27.9 85.6 58.2 0.9
PerkinElmer GSP Neonatal 651 261.8 16.9 17.5 0.4 1.0
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Table 17g. 2015 Quality Control Data Summaries of Statistical Analyses 
ALANINE (μmol Ala/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD
Y-  
Intercept* Slope
Derivatized - MS/MS non-kit 663 360.6 36.2 78.6 359.1 0.7
Non-derivatized - MS/MS non-kit 94 352.5 27.0 82.9 350.9 0.7
Derivatized - MS/MS PE NeoGram Kit 88 354.9 35.7 78.1 354.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 458 424.9 32.0 66.3 426.0 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 95 345.7 24.9 34.4 346.8 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 313.0 26.0 52.0 313.8 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 392.7 14.2 14.2 387.3 0.9
Lot 1426 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD
Y- 
 Intercept* Slope
Derivatized - MS/MS non-kit 658 497.6 45.7 95.5 359.1 0.7
Non-derivatized - MS/MS non-kit 94 483.8 43.1 113.9 350.9 0.7
Derivatized - MS/MS PE NeoGram Kit 90 507.3 56.3 117.7 354.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 461 605.8 46.2 94.8 426.0 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 97 487.5 37.5 56.5 346.8 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 440.0 42.1 80.3 313.8 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 542.0 19.4 19.4 387.3 0.9
Lot 1427 - Enriched 400.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 654 626.4 57.2 123.7 359.1 0.7
Non-derivatized - MS/MS non-kit 94 615.0 39.3 134.2 350.9 0.7
Derivatized - MS/MS PE NeoGram Kit 90 641.3 59.5 152.4 354.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 466 766.1 58.3 120.4 426.0 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 95 615.6 41.7 65.3 346.8 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 561.4 36.0 105.1 313.8 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 753.6 25.1 25.1 387.3 0.9
Lot 1428 - Enriched 600.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 651 774.9 64.7 149.3 359.1 0.7
Non-derivatized - MS/MS non-kit 95 754.5 68.2 200.2 350.9 0.7
Derivatized - MS/MS PE NeoGram Kit 90 806.0 75.3 183.0 354.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 465 951.8 67.9 146.8 426.0 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 96 759.1 50.9 96.9 346.8 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 687.2 39.0 117.8 313.8 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 899.0 37.2 37.2 387.3 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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ALANINE (μmol Ala/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 690 349.9 32.1 88.7 349.9 0.7
Non-derivatized - MS/MS non-kit 148 348.9 36.4 77.0 353.1 0.7
Derivatized - MS/MS PE NeoGram Kit 78 386.2 44.9 63.7 389.1 0.8
Non-derivatized - MS/MS PE NeoBase Kit 538 421.8 31.4 66.1 422.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 120 341.5 27.2 92.5 342.0 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 324.9 22.1 89.7 326.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 383.7 16.4 16.4 363.0 0.8
Lot 1522 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 679 492.7 43.5 112.4 349.9 0.7
Non-derivatized - MS/MS non-kit 149 499.6 57.0 124.8 353.1 0.7
Derivatized - MS/MS PE NeoGram Kit 78 542.4 56.3 94.8 389.1 0.8
Non-derivatized - MS/MS PE NeoBase Kit 539 602.8 42.6 91.9 422.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 119 477.3 34.2 124.7 342.0 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 470.1 32.1 132.3 326.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 500.0 24.1 24.1 363.0 0.8
Lot 1523 - Enriched 400.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 677 639.8 55.4 140.8 349.9 0.7
Non-derivatized - MS/MS non-kit 147 652.4 65.9 145.3 353.1 0.7
Derivatized - MS/MS PE NeoGram Kit 79 692.8 73.3 106.1 389.1 0.8
Non-derivatized - MS/MS PE NeoBase Kit 547 786.2 59.8 120.6 422.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 119 601.4 52.8 154.1 342.0 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 599.9 37.5 166.7 326.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 659.9 37.2 37.2 363.0 0.8
Lot 1428 - Enriched 600.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 685 780.2 74.9 178.2 349.9 0.7
Non-derivatized - MS/MS non-kit 150 781.2 72.4 192.8 353.1 0.7
Derivatized - MS/MS PE NeoGram Kit 80 837.4 93.1 166.2 389.1 0.8
Non-derivatized - MS/MS PE NeoBase Kit 548 960.3 68.9 136.8 422.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 119 740.5 52.5 176.0 342.0 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 744.0 44.3 199.7 326.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 10 858.1 46.5 46.5 363.0 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17h. 2015 Quality Control Data Summaries of Statistical Analyses 
ARGININE (μmol Arg/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 687 8.8 1.4 3.8 10.1 0.6
Non-derivatized - MS/MS non-kit 108 7.7 1.9 3.9 8.0 0.7
Derivatized - MS/MS PE NeoGram Kit 116 9.9 1.0 2.1 9.2 0.8
Non-derivatized - MS/MS PE NeoBase Kit 550 8.9 0.9 1.7 10.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 99 10.8 1.4 2.8 14.9 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 10.0 1.2 2.6 16.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 29 5.5 0.9 1.8 4.6 0.5
Lot 1426 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 711 74.1 8.2 28.2 10.1 0.6
Non-derivatized - MS/MS non-kit 119 77.1 6.9 18.7 8.0 0.7
Derivatized - MS/MS PE NeoGram Kit 116 90.9 6.7 16.8 9.2 0.8
Non-derivatized - MS/MS PE NeoBase Kit 560 96.2 6.2 10.6 10.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 99 100.0 13.2 23.1 14.9 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 90.5 7.7 18.0 16.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 48.7 3.0 3.7 4.6 0.5
Lot 1427 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 701 135.5 14.2 50.7 10.1 0.6
Non-derivatized - MS/MS non-kit 118 145.6 15.8 33.7 8.0 0.7
Derivatized - MS/MS PE NeoGram Kit 116 171.5 11.8 31.8 9.2 0.8
Non-derivatized - MS/MS PE NeoBase Kit 547 175.2 10.1 18.2 10.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 96 182.2 12.6 34.9 14.9 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 163.3 12.9 32.2 16.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 97.8 5.3 14.8 4.6 0.5
Lot 1428 - Enriched 600.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 690 196.1 18.5 74.3 10.1 0.6
Non-derivatized - MS/MS non-kit 119 214.3 21.7 48.5 8.0 0.7
Derivatized - MS/MS PE NeoGram Kit 119 256.2 18.3 47.5 9.2 0.8
Non-derivatized - MS/MS PE NeoBase Kit 553 257.3 15.2 28.6 10.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 96 254.2 17.0 56.0 14.9 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 91 215.0 14.1 39.8 16.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 142.5 11.1 24.2 4.6 0.5
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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ARGININE (μmol Arg/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 734 7.3 1.5 3.5 7.1 0.7
Non-derivatized - MS/MS non-kit 150 5.4 1.2 3.0 5.1 0.7
Derivatized - MS/MS PE NeoGram Kit 107 6.5 1.1 1.4 5.1 0.7
Non-derivatized - MS/MS PE NeoBase Kit 629 6.5 1.2 2.2 5.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 119 8.6 1.3 2.3 10.4 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 101 5.2 1.1 1.6 7.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 38 4.8 1.3 3.7 3.2 0.5
Lot 1522 - Enriched 100.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 777 71.3 9.4 27.1 7.1 0.7
Non-derivatized - MS/MS non-kit 158 77.1 8.4 18.7 5.1 0.7
Derivatized - MS/MS PE NeoGram Kit 109 77.2 8.2 14.9 5.1 0.7
Non-derivatized - MS/MS PE NeoBase Kit 628 86.9 5.9 12.9 5.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 120 97.9 8.2 18.9 10.4 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 104 82.8 7.3 12.1 7.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 47.2 4.7 6.4 3.2 0.5
Lot 1523 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 780 139.2 17.6 54.2 7.1 0.7
Non-derivatized - MS/MS non-kit 157 152.9 16.2 39.0 5.1 0.7
Derivatized - MS/MS PE NeoGram Kit 110 154.3 17.4 33.2 5.1 0.7
Non-derivatized - MS/MS PE NeoBase Kit 632 168.6 11.6 25.8 5.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 117 180.5 15.0 29.3 10.4 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 118 154.0 11.3 25.8 7.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 92.8 7.3 9.6 3.2 0.5
Lot 1524 - Enriched 300.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 773 202.2 25.8 80.1 7.1 0.7
Non-derivatized - MS/MS non-kit 156 223.7 24.3 56.7 5.1 0.7
Derivatized - MS/MS PE NeoGram Kit 107 228.7 24.4 42.3 5.1 0.7
Non-derivatized - MS/MS PE NeoBase Kit 626 251.6 17.9 36.4 5.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 120 263.8 24.2 48.6 10.4 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 120 222.7 15.7 40.5 7.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 141.5 11.2 19.4 3.2 0.5
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17i. 2015 Quality Control Data Summaries of Statistical Analyses 
CITRULLINE (μmol Cit/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 738 26.1 2.6 4.5 27.0 0.8
Non-derivatized - MS/MS non-kit 196 27.7 3.1 6.4 29.1 0.8
Derivatized - MS/MS PE NeoGram Kit 126 29.3 2.0 3.6 29.4 0.9
Non-derivatized - MS/MS PE NeoBase Kit 635 29.1 2.6 3.5 30.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 99 28.7 2.7 4.5 29.7 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 96 28.7 4.4 4.9 29.4 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 27.1 2.2 2.3 27.5 0.9
Lot 1426 - Enriched 25.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 737 46.9 4.5 8.2 27.0 0.8
Non-derivatized - MS/MS non-kit 198 50.6 4.4 9.0 29.1 0.8
Derivatized - MS/MS PE NeoGram Kit 129 53.4 3.8 6.8 29.4 0.9
Non-derivatized - MS/MS PE NeoBase Kit 630 54.3 4.0 5.8 30.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 97 51.9 4.1 6.5 29.7 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 96 52.4 8.4 9.1 29.4 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 47.7 4.5 4.9 27.5 0.9
Lot 1427 - Enriched 100.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 746 106.4 9.4 18.6 27.0 0.8
Non-derivatized - MS/MS non-kit 197 114.6 10.0 18.0 29.1 0.8
Derivatized - MS/MS PE NeoGram Kit 128 118.4 6.4 14.6 29.4 0.9
Non-derivatized - MS/MS PE NeoBase Kit 635 122.3 8.1 12.9 30.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 95 115.6 7.7 11.6 29.7 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 118.1 11.8 17.7 29.4 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 115.1 8.6 12.3 27.5 0.9
Lot 1428 - Enriched 250.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 745 222.4 17.2 36.6 27.0 0.8
Non-derivatized - MS/MS non-kit 198 238.2 18.6 33.8 29.1 0.8
Derivatized - MS/MS PE NeoGram Kit 128 257.1 16.4 32.8 29.4 0.9
Non-derivatized - MS/MS PE NeoBase Kit 631 258.7 16.7 25.8 30.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 97 243.7 14.1 27.2 29.7 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 251.2 27.7 35.4 29.4 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 239.8 15.9 22.7 27.5 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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CITRULLINE (μmol Cit/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 799 26.3 2.7 5.7 27.2 0.8
Non-derivatized - MS/MS non-kit 240 29.1 3.6 5.1 30.8 0.9
Derivatized - MS/MS PE NeoGram Kit 109 30.1 2.8 3.9 30.2 0.9
Non-derivatized - MS/MS PE NeoBase Kit 685 30.1 2.9 4.2 31.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 30.8 2.8 3.8 32.0 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 116 30.9 3.1 4.4 32.0 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 27.4 2.8 3.2 28.0 0.8
Lot 1522 - Enriched 25.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 799 46.6 4.4 9.8 27.2 0.8
Non-derivatized - MS/MS non-kit 245 52.4 5.0 8.3 30.8 0.9
Derivatized - MS/MS PE NeoGram Kit 107 51.0 4.4 6.6 30.2 0.9
Non-derivatized - MS/MS PE NeoBase Kit 689 54.7 4.5 6.7 31.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 54.5 4.2 7.5 32.0 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 53.9 4.3 7.3 32.0 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 47.8 3.1 4.1 28.0 0.8
Lot 1523 - Enriched 100.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 797 108.0 10.2 23.6 27.2 0.8
Non-derivatized - MS/MS non-kit 244 123.8 11.2 19.2 30.8 0.9
Derivatized - MS/MS PE NeoGram Kit 108 117.2 11.4 15.9 30.2 0.9
Non-derivatized - MS/MS PE NeoBase Kit 688 124.4 9.6 14.5 31.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 116 119.7 7.6 14.4 32.0 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 129 120.7 9.1 16.8 32.0 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 112.2 7.6 8.2 28.0 0.8
Lot 1524 - Enriched 250.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 790 223.3 21.4 46.3 27.2 0.8
Non-derivatized - MS/MS non-kit 250 251.9 22.9 40.2 30.8 0.9
Derivatized - MS/MS PE NeoGram Kit 108 244.2 23.9 37.9 30.2 0.9
Non-derivatized - MS/MS PE NeoBase Kit 684 259.5 18.0 28.5 31.4 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 249.0 17.2 26.1 32.0 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 127 249.2 17.6 35.0 32.0 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 232.7 15.5 25.6 28.0 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17j. 2015 Quality Control Data Summaries of Statistical Analyses 
LEUCINE (μmol Leu/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 767 146.3 11.7 23.6 147.7 0.8
Non-derivatized - MS/MS non-kit 275 178.8 11.5 25.7 180.8 0.9
Derivatized - MS/MS PE NeoGram Kit 125 143.5 13.0 15.9 142.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 626 177.3 10.6 17.1 179.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 93 140.5 13.0 22.2 140.1 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 168.3 12.7 23.2 170.2 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 170.8 14.8 22.8 170.4 0.9
Lot 1426 - Enriched 100.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 765 232.3 18.8 31.8 147.7 0.8
Non-derivatized - MS/MS non-kit 261 274.3 19.6 42.2 180.8 0.9
Derivatized - MS/MS PE NeoGram Kit 127 235.6 19.7 26.8 142.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 628 273.0 16.8 28.1 179.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 95 222.3 18.7 27.9 140.1 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 95 258.7 14.9 29.3 170.2 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 56 264.9 17.2 26.8 170.4 0.9
Lot 1427 - Enriched 250.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 755 350.0 27.7 46.8 147.7 0.8
Non-derivatized - MS/MS non-kit 272 398.5 27.1 58.4 180.8 0.9
Derivatized - MS/MS PE NeoGram Kit 127 359.9 24.5 39.5 142.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 623 400.6 24.3 38.7 179.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 94 327.7 26.3 33.1 140.1 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 384.1 25.1 51.5 170.2 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 402.6 41.2 62.8 170.4 0.9
Lot 1428 - Enriched 500.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 772 556.8 43.7 83.1 147.7 0.8
Non-derivatized - MS/MS non-kit 277 624.1 46.8 98.3 180.8 0.9
Derivatized - MS/MS PE NeoGram Kit 129 597.3 43.8 69.9 142.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 630 628.6 38.4 66.4 179.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 98 532.8 36.0 54.1 140.1 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 599.0 45.6 89.1 170.2 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 57 639.7 41.5 70.5 170.4 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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LEUCINE (μmol Leu/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 808 142.7 12.3 26.7 143.0 0.9
Non-derivatized - MS/MS non-kit 326 169.8 11.9 20.1 170.4 0.9
Derivatized - MS/MS PE NeoGram Kit 107 139.3 11.6 14.3 139.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 681 169.2 9.6 16.5 168.5 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 112 139.4 9.1 16.5 140.4 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 130 168.0 9.2 25.9 169.9 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 169.4 10.6 25.7 167.8 0.9
Lot 1522 - Enriched 100.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 811 230.4 18.1 35.6 143.0 0.9
Non-derivatized - MS/MS non-kit 324 260.9 18.2 29.5 170.4 0.9
Derivatized - MS/MS PE NeoGram Kit 110 227.1 18.4 26.1 139.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 675 259.8 15.8 25.7 168.5 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 115 219.0 17.2 25.4 140.4 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 126 258.6 13.0 33.8 169.9 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 261.2 12.7 31.9 167.8 0.9
Lot 1523 - Enriched 250.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 827 360.3 31.4 53.7 143.0 0.9
Non-derivatized - MS/MS non-kit 321 390.1 26.7 45.0 170.4 0.9
Derivatized - MS/MS PE NeoGram Kit 109 359.0 35.9 38.5 139.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 674 389.0 25.4 39.2 168.5 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 116 328.0 21.6 28.9 140.4 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 134 372.4 20.4 44.9 169.9 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 392.8 22.6 51.7 167.8 0.9
Lot 1524 - Enriched 500.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 819 577.8 46.1 92.6 143.0 0.9
Non-derivatized - MS/MS non-kit 325 613.9 41.2 82.2 170.4 0.9
Derivatized - MS/MS PE NeoGram Kit 109 580.3 56.5 67.7 139.0 0.9
Non-derivatized - MS/MS PE NeoBase Kit 670 619.0 41.2 58.5 168.5 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 115 520.9 34.7 45.9 140.4 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 129 586.3 31.0 49.2 169.9 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 630.4 38.5 84.6 167.8 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17k. 2015 Quality Control Data Summaries of Statistical Analyses 
METHIONINE (μmol Met/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 779 23.6 3.1 4.9 23.6 0.8
Non-derivatized - MS/MS non-kit 281 22.0 1.8 3.6 21.5 0.8
Derivatized - MS/MS PE NeoGram Kit 116 24.5 2.9 3.5 24.9 0.8
Non-derivatized - MS/MS PE NeoBase Kit 623 22.1 1.6 2.9 21.1 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 99 18.4 2.9 5.0 16.8 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 96 18.6 2.2 3.4 18.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 22.5 1.6 1.9 20.5 0.9
Lot 1426 - Enriched 50.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 764 64.1 5.7 9.4 23.6 0.8
Non-derivatized - MS/MS non-kit 272 62.9 4.6 12.1 21.5 0.8
Derivatized - MS/MS PE NeoGram Kit 116 67.4 6.8 8.7 24.9 0.8
Non-derivatized - MS/MS PE NeoBase Kit 625 63.2 4.2 8.0 21.1 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 97 48.5 7.8 14.5 16.8 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 54.7 4.4 9.6 18.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 61.9 4.3 5.2 20.5 0.9
Lot 1427 - Enriched 150.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 769 143.6 12.4 22.1 23.6 0.8
Non-derivatized - MS/MS non-kit 280 142.2 9.1 24.8 21.5 0.8
Derivatized - MS/MS PE NeoGram Kit 119 149.4 12.3 17.6 24.9 0.8
Non-derivatized - MS/MS PE NeoBase Kit 626 141.1 9.4 17.6 21.1 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 97 107.2 14.3 32.4 16.8 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 126.1 16.5 25.6 18.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 146.5 10.4 13.3 20.5 0.9
Lot 1428 - Enriched 250.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 769 224.7 17.6 33.5 23.6 0.8
Non-derivatized - MS/MS non-kit 279 227.9 15.0 41.8 21.5 0.8
Derivatized - MS/MS PE NeoGram Kit 119 233.7 19.4 28.8 24.9 0.8
Non-derivatized - MS/MS PE NeoBase Kit 631 229.8 14.6 29.2 21.1 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 99 177.0 23.5 47.9 16.8 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 198.2 18.8 32.5 18.7 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 235.8 11.6 17.6 20.5 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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METHIONINE (μmol Met/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 810 22.0 2.5 4.1 21.5 0.8
Non-derivatized - MS/MS non-kit 316 18.5 2.0 3.4 17.7 0.8
Derivatized - MS/MS PE NeoGram Kit 107 21.9 3.1 3.4 22.6 0.8
Non-derivatized - MS/MS PE NeoBase Kit 689 16.8 1.5 2.5 15.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 119 16.3 2.7 5.5 15.5 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 14.8 1.4 2.7 13.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 20.5 1.5 2.1 19.1 0.8
Lot 1522 - Enriched 50.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 805 62.2 5.7 9.9 21.5 0.8
Non-derivatized - MS/MS non-kit 307 58.5 5.0 9.8 17.7 0.8
Derivatized - MS/MS PE NeoGram Kit 110 63.6 7.3 9.1 22.6 0.8
Non-derivatized - MS/MS PE NeoBase Kit 672 55.0 3.7 7.3 15.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 120 44.1 6.2 16.1 15.5 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 120 48.7 3.3 8.3 13.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 59.8 3.4 5.7 19.1 0.8
Lot 1523 - Enriched 150.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 807 146.4 12.5 22.5 21.5 0.8
Non-derivatized - MS/MS non-kit 315 142.6 12.1 25.6 17.7 0.8
Derivatized - MS/MS PE NeoGram Kit 108 151.9 17.1 18.5 22.6 0.8
Non-derivatized - MS/MS PE NeoBase Kit 692 136.7 9.6 19.8 15.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 119 101.8 13.8 37.5 15.5 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 127 116.7 8.4 16.8 13.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 145.4 11.4 15.6 19.1 0.8
Lot 1524 - Enriched 250.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 808 229.1 19.7 36.9 21.5 0.8
Non-derivatized - MS/MS non-kit 318 226.1 18.2 39.9 17.7 0.8
Derivatized - MS/MS PE NeoGram Kit 109 230.0 24.9 31.5 22.6 0.8
Non-derivatized - MS/MS PE NeoBase Kit 684 217.9 15.6 30.2 15.8 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 120 161.3 21.0 58.5 15.5 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 130 192.0 14.0 32.3 13.4 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 230.7 12.5 23.6 19.1 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17l. 2015 Quality Control Data Summaries of Statistical Analyses 
PHENYLALANINE (μmol Phe/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average 
 Within  
Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 108 106.7 11.6 27.1 105.3 1.1
PerkinElmer Neonatal Kit 222 83.3 10.6 13.4 82.9 0.9
Ani Labsystems 117 92.2 11.9 22.2 91.6 1.3
Bio-Rad Quantase 30 98.8 14.6 17.9 99.4 1.1
Interscientific Enzyme 40 75.7 4.1 7.0 67.4 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 112.7 10.1 10.1 122.3 1.1
HPLC 10 79.7 4.2 4.2 76.5 1.0
Derivatized - MS/MS non-kit 844 74.1 5.8 10.2 74.0 0.9
Non-derivatized - MS/MS non-kit 345 77.8 5.5 11.6 78.3 1.0
Derivatized - MS/MS PE NeoGram Kit 156 78.3 6.3 9.8 76.7 1.0
Non-derivatized - MS/MS PE NeoBase Kit 640 75.6 4.9 7.5 76.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 81 77.6 6.2 13.5 80.3 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 84.7 6.3 10.2 84.6 1.0
TecnoSuma UMTEST 20 120.5 9.7 52.0 114.2 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 75.6 4.4 7.6 74.5 1.0




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 108 213.0 19.5 32.6 105.3 1.1
PerkinElmer Neonatal Kit 221 170.8 14.8 21.9 82.9 0.9
Ani Labsystems 119 226.8 21.1 36.4 91.6 1.3
Bio-Rad Quantase 28 210.9 17.0 20.8 99.4 1.1
Interscientific Enzyme 39 151.9 8.1 50.0 67.4 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 234.0 12.0 12.0 122.3 1.1
HPLC 10 172.2 9.4 9.4 76.5 1.0
Derivatized - MS/MS non-kit 836 164.4 12.4 21.9 74.0 0.9
Non-derivatized - MS/MS non-kit 338 177.2 10.1 24.2 78.3 1.0
Derivatized - MS/MS PE NeoGram Kit 157 174.0 11.4 20.2 76.7 1.0
Non-derivatized - MS/MS PE NeoBase Kit 640 170.9 11.3 17.2 76.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 87 171.6 16.0 31.9 80.3 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 188.2 15.4 24.5 84.6 1.0
TecnoSuma UMTEST 20 235.7 15.0 97.0 114.2 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 167.5 10.8 15.8 74.5 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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PHENYLALANINE (μmol Phe/L blood)




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 97 320.1 29.4 45.2 105.3 1.1
PerkinElmer Neonatal Kit 221 261.2 20.2 31.3 82.9 0.9
Ani Labsystems 120 352.5 25.6 58.9 91.6 1.3
Bio-Rad Quantase 30 317.9 15.8 26.3 99.4 1.1
Interscientific Enzyme 40 261.9 10.2 18.8 67.4 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 350.6 21.5 21.5 122.3 1.1
HPLC 10 272.9 9.8 9.8 76.5 1.0
Derivatized - MS/MS non-kit 845 253.2 20.3 35.3 74.0 0.9
Non-derivatized - MS/MS non-kit 342 269.4 16.4 39.0 78.3 1.0
Derivatized - MS/MS PE NeoGram Kit 155 268.4 16.7 30.8 76.7 1.0
Non-derivatized - MS/MS PE NeoBase Kit 638 262.4 16.4 27.3 76.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 82 251.7 17.0 35.8 80.3 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 288.7 14.9 26.9 84.6 1.0
TecnoSuma UMTEST 20 375.6 16.9 91.0 114.2 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 267.4 18.4 22.4 74.5 1.0




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 108 433.2 43.4 53.3 105.3 1.1
PerkinElmer Neonatal Kit 219 349.2 28.8 46.0 82.9 0.9
Ani Labsystems 120 494.6 28.7 79.5 91.6 1.3
Bio-Rad Quantase 27 429.3 18.3 33.8 99.4 1.1
Interscientific Enzyme 30 364.7 10.5 20.8 67.4 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 426.2 20.9 20.9 122.3 1.1
HPLC 10 377.1 15.3 15.3 76.5 1.0
Derivatized - MS/MS non-kit 853 344.5 25.2 52.5 74.0 0.9
Non-derivatized - MS/MS non-kit 346 370.0 24.0 56.0 78.3 1.0
Derivatized - MS/MS PE NeoGram Kit 155 372.9 27.9 44.6 76.7 1.0
Non-derivatized - MS/MS PE NeoBase Kit 636 357.1 21.4 35.0 76.1 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 83 339.7 24.0 62.5 80.3 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 394.0 23.8 32.2 84.6 1.0
TecnoSuma UMTEST 20 509.6 42.8 121.1 114.2 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 360.7 17.6 26.9 74.5 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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PHENYLALANINE (μmol Phe/L blood)




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 79 93.9 8.9 18.3 90.7 1.1
PerkinElmer Neonatal Kit 155 75.1 9.4 11.3 74.9 0.9
Ani Labsystems 79 82.3 9.2 12.8 81.0 1.3
Bio-Rad Quantase 29 84.2 10.9 10.9 82.7 1.1
Interscientific Enzyme 30 78.1 3.8 3.8 70.9 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 100.9 3.5 3.5 97.7 1.1
HPLC 10 81.8 4.0 4.0 84.2 0.9
Derivatized - MS/MS non-kit 888 71.4 5.8 11.0 70.8 0.9
Non-derivatized - MS/MS non-kit 384 74.5 5.1 9.8 74.8 1.0
Derivatized - MS/MS PE NeoGram Kit 119 73.8 7.5 11.0 73.2 1.0
Non-derivatized - MS/MS PE NeoBase Kit 708 71.1 4.4 7.7 69.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 110 68.7 5.8 8.0 68.8 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 79.9 4.7 8.5 80.3 1.0
TecnoSuma UMTEST 10 74.6 9.9 9.9 69.8 1.1
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 74.3 5.1 7.1 73.0 1.0




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 77 197.6 17.4 19.4 90.7 1.1
PerkinElmer Neonatal Kit 159 165.4 20.1 25.9 74.9 0.9
Ani Labsystems 79 212.0 16.2 30.8 81.0 1.3
Bio-Rad Quantase 30 191.2 26.0 38.1 82.7 1.1
Interscientific Enzyme 30 166.8 5.6 13.0 70.9 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 196.2 6.1 6.1 97.7 1.1
HPLC 10 175.4 8.1 8.1 84.2 0.9
Derivatized - MS/MS non-kit 888 162.9 12.0 24.2 70.8 0.9
Non-derivatized - MS/MS non-kit 388 173.6 11.0 21.5 74.8 1.0
Derivatized - MS/MS PE NeoGram Kit 120 167.3 15.6 25.9 73.2 1.0
Non-derivatized - MS/MS PE NeoBase Kit 707 163.5 10.0 18.3 69.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 111 155.5 12.8 26.1 68.8 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 183.6 9.8 18.5 80.3 1.0
TecnoSuma UMTEST 10 173.4 20.0 20.0 69.8 1.1
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 168.8 8.7 17.6 73.0 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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PHENYLALANINE (μmol Phe/L blood)




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 68 318.0 28.3 32.1 90.7 1.1
PerkinElmer Neonatal Kit 150 244.7 21.1 33.3 74.9 0.9
Ani Labsystems 80 337.4 27.3 53.0 81.0 1.3
Bio-Rad Quantase 29 286.0 21.8 25.7 82.7 1.1
Interscientific Enzyme 30 264.4 6.2 27.8 70.9 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 320.0 8.8 8.8 97.7 1.1
HPLC 10 274.4 15.7 15.7 84.2 0.9
Derivatized - MS/MS non-kit 889 254.3 19.5 39.8 70.8 0.9
Non-derivatized - MS/MS non-kit 384 271.2 17.7 31.4 74.8 1.0
Derivatized - MS/MS PE NeoGram Kit 119 263.5 27.9 39.3 73.2 1.0
Non-derivatized - MS/MS PE NeoBase Kit 709 254.1 16.5 27.2 69.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 110 237.0 16.8 37.7 68.8 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 278.6 17.5 29.4 80.3 1.0
TecnoSuma UMTEST 10 291.3 48.0 48.0 69.8 1.1
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 263.2 15.0 26.5 73.0 1.0




Lab SD Total SD Y- Intercept* Slope
Fluorometric Manual 80 429.5 31.3 62.1 90.7 1.1
PerkinElmer Neonatal Kit 155 342.0 33.5 47.8 74.9 0.9
Ani Labsystems 80 475.9 38.3 74.2 81.0 1.3
Bio-Rad Quantase 29 406.7 20.9 25.9 82.7 1.1
Interscientific Enzyme 28 385.2 7.8 11.8 70.9 1.0
Astoria-Pacific 50 Hour Reagent Kit 10 417.3 15.3 15.3 97.7 1.1
HPLC 10 353.5 18.5 18.5 84.2 0.9
Derivatized - MS/MS non-kit 893 348.9 27.8 56.6 70.8 0.9
Non-derivatized - MS/MS non-kit 388 369.6 24.8 47.6 74.8 1.0
Derivatized - MS/MS PE NeoGram Kit 120 358.8 39.1 55.8 73.2 1.0
Non-derivatized - MS/MS PE NeoBase Kit 708 353.1 23.3 37.5 69.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 111 325.9 25.2 58.2 68.8 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 384.6 22.8 47.6 80.3 1.0
TecnoSuma UMTEST 10 404.5 36.1 36.1 69.8 1.1
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 363.9 23.1 37.8 73.0 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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SUCCINYLACETONE (μmol SUAC/L blood)




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 237 0.7 0.2 0.5 0.8 0.5
Non-derivatized - MS/MS non-kit 68 1.0 0.3 0.9 1.1 0.5
Non-derivatized - MS/MS PE NeoBase Kit 395 0.5 0.1 0.3 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 40 0.5 0.2 0.4 0.6 0.4




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 233 2.1 0.3 1.2 0.8 0.5
Non-derivatized - MS/MS non-kit 70 2.4 0.4 0.9 1.1 0.5
Non-derivatized - MS/MS PE NeoBase Kit 395 1.0 0.2 0.3 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 38 1.6 0.2 0.2 0.6 0.4




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 238 5.0 0.6 2.8 0.8 0.5
Non-derivatized - MS/MS non-kit 70 4.9 0.7 1.8 1.1 0.5
Non-derivatized - MS/MS PE NeoBase Kit 393 2.0 0.3 0.7 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 38 3.6 0.4 0.5 0.6 0.4




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 237 8.8 1.0 4.9 0.8 0.5
Non-derivatized - MS/MS non-kit 70 8.8 1.2 3.7 1.1 0.5
Non-derivatized - MS/MS PE NeoBase Kit 389 3.5 0.4 1.1 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 39 6.2 0.5 1.3 0.6 0.4
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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SUCCINYLACETONE (μmol SUAC/L blood)




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 241 0.7 0.2 0.5 0.9 0.5
Non-derivatized - MS/MS non-kit 76 0.9 0.3 0.8 1.0 0.4
Non-derivatized - MS/MS PE NeoBase Kit 390 0.5 0.1 0.3 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 70 0.5 0.1 0.3 0.6 0.4




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 235 2.3 0.3 1.2 0.9 0.5
Non-derivatized - MS/MS non-kit 80 2.2 0.4 1.1 1.0 0.4
Non-derivatized - MS/MS PE NeoBase Kit 396 1.0 0.2 0.3 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 70 1.7 0.2 0.5 0.6 0.4




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 240 5.0 0.7 2.8 0.9 0.5
Non-derivatized - MS/MS non-kit 80 4.3 0.7 2.4 1.0 0.4
Non-derivatized - MS/MS PE NeoBase Kit 404 2.0 0.3 0.7 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 70 3.5 0.4 0.8 0.6 0.4




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 236 8.7 1.2 4.8 0.9 0.5
Non-derivatized - MS/MS non-kit 79 7.4 1.2 4.8 1.0 0.4
Non-derivatized - MS/MS PE NeoBase Kit 390 3.6 0.4 1.1 0.5 0.2
Derivatized - MS/MS Chromsystems MassChrom Kit 70 6.4 0.4 1.7 0.6 0.4
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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TYROSINE (μmol Tyr/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 83.1 3.7 3.7 82.1 0.9
Derivatized - MS/MS non-kit 809 55.1 4.7 7.7 57.4 0.8
Non-derivatized - MS/MS non-kit 301 56.8 4.5 7.8 59.4 0.8
Derivatized - MS/MS PE NeoGram Kit 128 56.2 5.5 8.0 56.0 0.8
Non-derivatized - MS/MS PE NeoBase Kit 631 61.7 4.3 7.1 63.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 95 61.2 6.6 9.0 64.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 62.8 7.1 10.6 61.9 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 68 55.3 3.7 5.2 56.6 0.8
Lot 1426 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 262.3 12.2 12.2 82.1 0.9
Derivatized - MS/MS non-kit 831 220.0 17.6 30.1 57.4 0.8
Non-derivatized - MS/MS non-kit 292 229.6 14.9 37.8 59.4 0.8
Derivatized - MS/MS PE NeoGram Kit 127 225.8 19.9 28.5 56.0 0.8
Non-derivatized - MS/MS PE NeoBase Kit 638 252.1 16.7 29.3 63.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 98 242.5 17.6 27.7 64.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 251.3 28.3 42.0 61.9 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 70 223.8 15.2 21.8 56.6 0.8
Lot 1427 - Enriched 400.0 μmol/L blood
METHOD N Mean
Average  Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 9 444.1 14.7 14.7 82.1 0.9
Derivatized - MS/MS non-kit 816 379.3 28.3 49.5 57.4 0.8
Non-derivatized - MS/MS non-kit 302 392.6 26.9 68.6 59.4 0.8
Derivatized - MS/MS PE NeoGram Kit 130 389.2 26.4 45.5 56.0 0.8
Non-derivatized - MS/MS PE NeoBase Kit 638 432.3 27.8 51.2 63.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 98 412.6 32.1 43.5 64.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 94 439.5 40.9 79.3 61.9 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 70 396.5 21.9 30.3 56.6 0.8
Lot 1428 - Enriched 600.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 627.0 26.2 26.2 82.1 0.9
Derivatized - MS/MS non-kit 821 535.6 37.4 76.0 57.4 0.8
Non-derivatized - MS/MS non-kit 307 557.1 44.8 95.8 59.4 0.8
Derivatized - MS/MS PE NeoGram Kit 129 562.9 42.0 69.0 56.0 0.8
Non-derivatized - MS/MS PE NeoBase Kit 637 617.0 37.6 69.1 63.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 97 581.4 47.4 83.3 64.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 98 632.7 46.0 98.0 61.9 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 69 556.5 25.1 40.2 56.6 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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TYROSINE (μmol Tyr/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 91.4 5.5 5.5 95.4 0.8
Derivatized - MS/MS non-kit 824 53.3 4.9 7.9 52.3 0.8
Non-derivatized - MS/MS non-kit 346 56.7 4.7 8.3 55.3 0.9
Derivatized - MS/MS PE NeoGram Kit 107 54.5 6.0 7.2 54.8 0.8
Non-derivatized - MS/MS PE NeoBase Kit 712 58.9 4.6 8.6 56.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 119 59.9 4.9 9.1 59.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 118 61.2 4.0 6.7 59.4 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 52.7 2.5 5.5 48.9 0.8
Lot 1522 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 262.5 10.9 10.9 95.4 0.8
Derivatized - MS/MS non-kit 828 216.9 16.7 32.2 52.3 0.8
Non-derivatized - MS/MS non-kit 346 232.9 17.1 32.9 55.3 0.9
Derivatized - MS/MS PE NeoGram Kit 108 218.9 20.9 25.8 54.8 0.8
Non-derivatized - MS/MS PE NeoBase Kit 704 240.0 15.7 30.8 56.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 120 242.7 20.3 41.4 59.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 120 251.3 17.6 32.1 59.4 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 209.1 9.4 18.9 48.9 0.8
Lot 1523 - Enriched 400.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 441.7 27.7 27.7 95.4 0.8
Derivatized - MS/MS non-kit 837 386.8 30.8 57.9 52.3 0.8
Non-derivatized - MS/MS non-kit 338 407.5 28.5 52.4 55.3 0.9
Derivatized - MS/MS PE NeoGram Kit 108 390.0 40.8 51.8 54.8 0.8
Non-derivatized - MS/MS PE NeoBase Kit 710 423.7 27.5 52.9 56.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 413.4 33.5 56.6 59.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 127 429.2 33.5 55.8 59.4 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 370.6 18.3 36.4 48.9 0.8
Lot 1524 - Enriched 600.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
HPLC 10 588.6 29.0 29.0 95.4 0.8
Derivatized - MS/MS non-kit 839 552.3 43.9 87.5 52.3 0.8
Non-derivatized - MS/MS non-kit 342 591.5 42.1 80.3 55.3 0.9
Derivatized - MS/MS PE NeoGram Kit 107 549.4 50.5 71.7 54.8 0.8
Non-derivatized - MS/MS PE NeoBase Kit 712 613.7 41.5 81.8 56.9 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 602.2 40.1 87.2 59.9 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 130 633.4 44.5 78.6 59.4 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 543.6 26.3 62.3 48.9 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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VALINE (μmol Val/L blood)
Lot 1425 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 711 158.6 15.7 28.0 160.9 0.7
Non-derivatized - MS/MS non-kit 188 144.3 8.4 25.4 146.6 0.7
Derivatized - MS/MS PE NeoGram Kit 115 165.2 19.1 22.9 168.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 627 175.6 13.4 23.2 179.8 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 93 135.9 12.5 22.3 138.9 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 131.2 10.9 19.6 136.0 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 176.4 11.3 21.2 175.7 0.9
Lot 1426 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 717 305.8 28.6 52.7 160.9 0.7
Non-derivatized - MS/MS non-kit 186 294.8 19.2 50.0 146.6 0.7
Derivatized - MS/MS PE NeoGram Kit 118 323.1 38.8 48.2 168.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 630 365.9 29.1 51.9 179.8 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 99 281.2 33.4 57.0 138.9 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 272.0 19.8 46.9 136.0 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 354.5 23.9 45.4 175.7 0.9
Lot 1427 - Enriched 350.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 715 402.1 40.5 68.6 160.9 0.7
Non-derivatized - MS/MS non-kit 188 392.9 22.2 65.4 146.6 0.7
Derivatized - MS/MS PE NeoGram Kit 118 425.0 39.0 61.1 168.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 632 484.1 40.2 70.5 179.8 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 96 357.9 38.8 72.3 138.9 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 364.3 22.1 57.6 136.0 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 498.7 27.9 60.2 175.7 0.9
Lot 1428 - Enriched 500.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 716 509.8 45.1 83.2 160.9 0.7
Non-derivatized - MS/MS non-kit 189 503.0 33.6 89.8 146.6 0.7
Derivatized - MS/MS PE NeoGram Kit 117 538.5 55.8 80.9 168.3 0.7
Non-derivatized - MS/MS PE NeoBase Kit 627 621.1 46.9 84.4 179.8 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 96 472.5 42.8 91.3 138.9 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 454.6 24.6 73.0 136.0 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 629.7 34.2 66.2 175.7 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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VALINE (μmol Val/L blood)
Lot 1521 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 771 164.1 15.8 30.2 160.2 0.7
Non-derivatized - MS/MS non-kit 238 147.1 11.4 29.6 145.5 0.7
Derivatized - MS/MS PE NeoGram Kit 97 173.7 21.1 26.6 169.9 0.7
Non-derivatized - MS/MS PE NeoBase Kit 686 172.8 13.5 23.8 166.7 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 110 143.4 18.4 35.7 140.6 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 124.8 8.2 13.8 121.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 186.0 10.3 20.3 180.3 0.9
Lot 1522 - Enriched 200.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 775 302.1 30.1 55.2 160.2 0.7
Non-derivatized - MS/MS non-kit 239 289.1 22.4 58.8 145.5 0.7
Derivatized - MS/MS PE NeoGram Kit 97 307.5 36.7 50.8 169.9 0.7
Non-derivatized - MS/MS PE NeoBase Kit 709 334.0 29.4 56.5 166.7 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 110 265.4 26.4 65.8 140.6 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 251.9 15.3 34.6 121.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 355.2 17.5 35.6 180.3 0.9
Lot 1523 - Enriched 350.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 790 418.1 42.4 84.2 160.2 0.7
Non-derivatized - MS/MS non-kit 237 405.7 32.6 84.4 145.5 0.7
Derivatized - MS/MS PE NeoGram Kit 100 427.6 50.5 69.7 169.9 0.7
Non-derivatized - MS/MS PE NeoBase Kit 684 471.8 37.1 67.2 166.7 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 109 359.2 42.6 88.7 140.6 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 119 354.2 25.0 50.5 121.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 491.5 30.0 50.0 180.3 0.9
Lot 1524 - Enriched 500.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 790 533.2 57.7 108.9 160.2 0.7
Non-derivatized - MS/MS non-kit 240 513.9 37.6 106.8 145.5 0.7
Derivatized - MS/MS PE NeoGram Kit 100 534.5 69.4 95.7 169.9 0.7
Non-derivatized - MS/MS PE NeoBase Kit 679 611.7 49.8 86.9 166.7 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 110 463.1 43.9 116.3 140.6 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 118 459.5 29.0 58.2 121.6 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 640.4 44.0 68.7 180.3 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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FREE CARNITINE (μmol C0/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 846 16.46 1.67 2.87 16.17 1.3
Non-derivatized - MS/MS non-kit 209 15.73 1.23 2.91 15.47 1.1
Derivatized - MS/MS PE NeoGram Kit 130 21.19 1.82 3.29 20.18 1.8
Non-derivatized - MS/MS PE NeoBase Kit 633 15.29 1.29 1.94 15.09 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 106 14.84 1.76 3.05 14.80 1.1
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 13.43 1.01 1.71 13.71 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 16.13 0.79 1.66 15.97 1.1
Lot 1466 - Enriched 10.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 847 28.71 2.71 4.67 16.17 1.3
Non-derivatized - MS/MS non-kit 206 25.92 1.84 4.12 15.47 1.1
Derivatized - MS/MS PE NeoGram Kit 128 37.58 2.79 5.94 20.18 1.8
Non-derivatized - MS/MS PE NeoBase Kit 633 25.29 2.02 3.08 15.09 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 110 26.00 2.86 5.54 14.80 1.1
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 23.52 1.49 3.14 13.71 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 26.83 2.13 3.26 15.97 1.1
Lot 1467 - Enriched 20.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 833 41.50 3.90 6.83 16.17 1.3
Non-derivatized - MS/MS non-kit 203 36.24 2.51 5.70 15.47 1.1
Derivatized - MS/MS PE NeoGram Kit 129 56.03 4.46 9.98 20.18 1.8
Non-derivatized - MS/MS PE NeoBase Kit 630 35.50 2.70 4.04 15.09 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 108 37.49 3.48 8.47 14.80 1.1
Non-derivatized - MS/MS Chromsystems MassChrom Kit 86 31.40 2.43 4.88 13.71 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 37.28 2.04 3.70 15.97 1.1
Lot 1468 - Enriched 30.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 850 54.96 4.76 9.71 16.17 1.3
Non-derivatized - MS/MS non-kit 207 47.68 3.38 8.54 15.47 1.1
Derivatized - MS/MS PE NeoGram Kit 130 76.46 5.95 12.97 20.18 1.8
Non-derivatized - MS/MS PE NeoBase Kit 644 46.38 3.98 6.16 15.09 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 108 48.68 4.70 10.45 14.80 1.1
Non-derivatized - MS/MS Chromsystems MassChrom Kit 86 41.22 2.87 6.61 13.71 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 48.91 3.11 6.59 15.97 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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FREE CARNITINE (μmol C0/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD
Y-  
Intercept* Slope
Derivatized - MS/MS non-kit 913 16.87 1.80 3.47 16.74 1.4
Non-derivatized - MS/MS non-kit 256 15.27 1.41 3.04 15.40 1.1
Derivatized - MS/MS PE NeoGram Kit 109 19.67 1.75 3.02 19.23 1.9
Non-derivatized - MS/MS PE NeoBase Kit 700 13.96 1.11 2.00 14.15 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 128 14.23 1.34 3.31 14.01 1.2
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 13.29 0.87 1.56 13.41 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 14.77 1.19 2.09 14.88 1.1
Lot 1562 - Enriched 10.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD
Y-  
Intercept* Slope
Derivatized - MS/MS non-kit 914 31.10 3.02 5.88 16.74 1.4
Non-derivatized - MS/MS non-kit 259 26.67 2.49 5.85 15.40 1.1
Derivatized - MS/MS PE NeoGram Kit 110 37.93 3.72 6.72 19.23 1.9
Non-derivatized - MS/MS PE NeoBase Kit 698 24.64 1.90 3.36 14.15 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 129 25.55 2.51 6.10 14.01 1.2
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 23.32 1.21 2.40 13.41 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 25.90 1.44 3.44 14.88 1.1
Lot 1563 - Enriched 20.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD
Y-  
Intercept* Slope
Derivatized - MS/MS non-kit 913 44.86 3.99 8.03 16.74 1.4
Non-derivatized - MS/MS non-kit 260 37.64 2.75 7.67 15.40 1.1
Derivatized - MS/MS PE NeoGram Kit 110 55.59 4.72 10.52 19.23 1.9
Non-derivatized - MS/MS PE NeoBase Kit 704 35.00 2.41 4.76 14.15 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 130 37.66 3.70 9.22 14.01 1.2
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 32.52 2.21 3.86 13.41 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 37.07 2.26 4.32 14.88 1.1
Lot 1564 - Enriched 30.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD
Y-  
Intercept* Slope
Derivatized - MS/MS non-kit 911 59.98 5.70 11.54 16.74 1.4
Non-derivatized - MS/MS non-kit 260 48.62 3.77 9.71 15.40 1.1
Derivatized - MS/MS PE NeoGram Kit 107 76.34 6.58 12.83 19.23 1.9
Non-derivatized - MS/MS PE NeoBase Kit 696 44.89 3.29 5.95 14.15 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 129 49.66 4.24 12.30 14.01 1.2
Non-derivatized - MS/MS Chromsystems MassChrom Kit 109 42.37 2.49 4.14 13.41 1.0
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 47.64 3.06 5.56 14.88 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201676
Table 17q. 2015 Quality Control Data Summaries of Statistical Analyses 
ACETYLCARNITINE (μmol C2/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 813 11.52 1.34 2.99 11.76 0.9
Non-derivatized - MS/MS non-kit 200 9.05 0.71 1.75 9.17 1.0
Derivatized - MS/MS PE NeoGram Kit 130 14.44 1.05 2.86 14.40 0.6
Non-derivatized - MS/MS PE NeoBase Kit 640 8.38 0.56 0.94 8.49 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 105 11.18 1.32 2.40 11.39 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 7.50 0.58 1.06 7.68 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 11.06 0.62 1.83 11.08 1.1
Lot 1466 - Enriched 10.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 817 20.89 2.19 4.75 11.76 0.9
Non-derivatized - MS/MS non-kit 198 19.02 1.36 3.29 9.17 1.0
Derivatized - MS/MS PE NeoGram Kit 128 20.99 1.27 2.84 14.40 0.6
Non-derivatized - MS/MS PE NeoBase Kit 652 17.58 1.10 2.06 8.49 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 108 20.32 1.99 2.94 11.39 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 16.56 1.03 1.92 7.68 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 22.09 1.45 3.00 11.08 1.1
Lot 1467 - Enriched 20.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 814 29.33 2.91 5.72 11.76 0.9
Non-derivatized - MS/MS non-kit 196 27.90 1.89 4.85 9.17 1.0
Derivatized - MS/MS PE NeoGram Kit 127 26.74 1.62 3.36 14.40 0.6
Non-derivatized - MS/MS PE NeoBase Kit 646 26.44 1.67 2.95 8.49 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 110 28.28 2.51 4.05 11.39 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 86 23.74 1.61 2.98 7.68 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 32.91 2.11 3.65 11.08 1.1
Lot 1468 - Enriched 30.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 816 37.99 3.50 7.30 11.76 0.9
Non-derivatized - MS/MS non-kit 198 37.81 2.63 7.15 9.17 1.0
Derivatized - MS/MS PE NeoGram Kit 130 33.88 2.03 4.03 14.40 0.6
Non-derivatized - MS/MS PE NeoBase Kit 642 35.24 2.31 4.02 8.49 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 107 36.97 3.16 4.13 11.39 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 32.89 2.10 3.57 7.68 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 43.95 2.63 4.14 11.08 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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ACETYLCARNITINE (μmol C2/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 890 12.98 1.63 3.48 12.73 1.0
Non-derivatized - MS/MS non-kit 250 11.24 0.97 1.96 10.88 1.1
Derivatized - MS/MS PE NeoGram Kit 106 14.44 1.47 2.18 14.52 0.7
Non-derivatized - MS/MS PE NeoBase Kit 674 9.07 0.54 1.00 8.74 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 121 10.74 0.75 1.73 10.28 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 8.69 0.65 1.22 8.51 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 11.05 0.58 0.76 10.68 1.1
Lot 1562 - Enriched 10.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 868 22.24 2.10 4.09 12.73 1.0
Non-derivatized - MS/MS non-kit 245 21.41 1.47 3.17 10.88 1.1
Derivatized - MS/MS PE NeoGram Kit 105 21.76 2.29 3.00 14.52 0.7
Non-derivatized - MS/MS PE NeoBase Kit 680 17.92 1.09 1.90 8.74 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 122 19.35 1.41 2.99 10.28 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 109 16.95 1.07 1.89 8.51 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 21.60 1.02 1.65 10.68 1.1
Lot 1563 - Enriched 20.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 880 31.48 2.98 6.24 12.73 1.0
Non-derivatized - MS/MS non-kit 246 32.31 2.50 5.00 10.88 1.1
Derivatized - MS/MS PE NeoGram Kit 105 27.72 2.10 3.57 14.52 0.7
Non-derivatized - MS/MS PE NeoBase Kit 685 26.99 1.58 2.82 8.74 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 121 27.93 1.99 3.51 10.28 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 106 25.21 1.49 2.92 8.51 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 33.24 1.98 2.39 10.68 1.1
Lot 1564 - Enriched 30.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 875 42.01 3.52 7.50 12.73 1.0
Non-derivatized - MS/MS non-kit 248 43.92 3.07 6.29 10.88 1.1
Derivatized - MS/MS PE NeoGram Kit 107 35.32 3.36 4.14 14.52 0.7
Non-derivatized - MS/MS PE NeoBase Kit 676 37.39 2.17 3.95 8.74 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 128 38.84 2.53 5.65 10.28 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 95 34.40 2.24 3.59 8.51 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 45.10 2.32 3.06 10.68 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201678
Table 17r. 2015 Quality Control Data Summaries of Statistical Analyses 
PROPIONYLCARNITINE (μmol C3/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 819 0.95 0.12 0.18 1.02 0.9
Non-derivatized - MS/MS non-kit 205 0.92 0.09 0.17 0.94 1.0
Derivatized - MS/MS PE NeoGram Kit 125 0.78 0.08 0.11 0.77 0.8
Non-derivatized - MS/MS PE NeoBase Kit 636 0.78 0.06 0.09 0.78 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 105 0.90 0.16 0.20 0.86 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.80 0.08 0.14 0.80 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 1.01 0.07 0.10 1.02 1.0
Lot 1466 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 819 3.88 0.42 0.64 1.02 0.9
Non-derivatized - MS/MS non-kit 206 3.90 0.27 0.63 0.94 1.0
Derivatized - MS/MS PE NeoGram Kit 127 3.25 0.24 0.37 0.77 0.8
Non-derivatized - MS/MS PE NeoBase Kit 650 3.30 0.22 0.36 0.78 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 106 3.39 0.32 0.42 0.86 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 3.36 0.34 0.53 0.80 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 4.12 0.29 0.36 1.02 1.0
Lot 1467 - Enriched 7.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 822 8.14 0.89 1.41 1.02 0.9
Non-derivatized - MS/MS non-kit 201 8.16 0.66 1.29 0.94 1.0
Derivatized - MS/MS PE NeoGram Kit 126 6.76 0.47 0.83 0.77 0.8
Non-derivatized - MS/MS PE NeoBase Kit 647 7.00 0.47 0.74 0.78 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 7.00 0.70 0.78 0.86 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 7.01 0.56 1.22 0.80 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 8.66 0.54 0.58 1.02 1.0
Lot 1468 - Enriched 12.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 829 12.20 1.26 2.14 1.02 0.9
Non-derivatized - MS/MS non-kit 202 12.57 1.01 2.25 0.94 1.0
Derivatized - MS/MS PE NeoGram Kit 129 10.61 0.85 1.21 0.77 0.8
Non-derivatized - MS/MS PE NeoBase Kit 645 10.82 0.68 1.15 0.78 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 10.97 1.07 1.37 0.86 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 10.94 0.78 1.59 0.80 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 13.32 0.76 0.85 1.02 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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PROPIONYLCARNITINE (μmol C3/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 894 1.02 0.12 0.19 0.90 1.0
Non-derivatized - MS/MS non-kit 251 1.01 0.10 0.17 0.91 1.1
Derivatized - MS/MS PE NeoGram Kit 103 0.78 0.08 0.11 0.68 0.8
Non-derivatized - MS/MS PE NeoBase Kit 704 0.82 0.06 0.10 0.71 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 117 0.92 0.11 0.12 0.77 1.0
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 0.86 0.08 0.15 0.70 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 47 1.03 0.04 0.08 0.89 1.1
Lot 1562 - Enriched 4.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 893 5.04 0.51 0.85 0.90 1.0
Non-derivatized - MS/MS non-kit 244 5.11 0.40 0.82 0.91 1.1
Derivatized - MS/MS PE NeoGram Kit 103 4.08 0.42 0.57 0.68 0.8
Non-derivatized - MS/MS PE NeoBase Kit 709 4.24 0.28 0.49 0.71 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 117 4.49 0.38 0.50 0.77 1.0
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 4.32 0.27 0.57 0.70 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 5.37 0.26 0.53 0.89 1.1
Lot 1563 - Enriched 8.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 901 8.91 0.89 1.45 0.90 1.0
Non-derivatized - MS/MS non-kit 251 9.39 0.78 1.66 0.91 1.1
Derivatized - MS/MS PE NeoGram Kit 103 7.04 0.56 1.28 0.68 0.8
Non-derivatized - MS/MS PE NeoBase Kit 704 7.59 0.45 0.83 0.71 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 116 8.06 0.62 0.83 0.77 1.0
Non-derivatized - MS/MS Chromsystems MassChrom Kit 106 7.77 0.48 1.17 0.70 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 9.64 0.48 0.87 0.89 1.1
Lot 1564 - Enriched 12.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 902 13.61 1.36 2.18 0.90 1.0
Non-derivatized - MS/MS non-kit 248 13.95 1.01 2.18 0.91 1.1
Derivatized - MS/MS PE NeoGram Kit 107 11.01 1.04 1.96 0.68 0.8
Non-derivatized - MS/MS PE NeoBase Kit 702 11.61 0.70 1.29 0.71 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 117 12.39 0.91 1.44 0.77 1.0
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 12.08 0.79 1.67 0.70 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 14.68 0.79 1.32 0.89 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201680
Table 17s. 2015 Quality Control Data Summaries of Statistical Analyses 
MALONYLCARNITINE (μmol C3DC/L blood)




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 750 0.03 0.01 0.02 0.05 0.5
Derivatized - MS/MS PE NeoGram Kit 112 0.04 0.01 0.01 0.07 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 96 0.04 0.02 0.03 0.06 0.6




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 746 0.31 0.06 0.10 0.05 0.5
Derivatized - MS/MS PE NeoGram Kit 120 0.68 0.07 0.19 0.07 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 97 0.36 0.08 0.14 0.06 0.6




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 744 0.91 0.15 0.28 0.05 0.5
Derivatized - MS/MS PE NeoGram Kit 120 2.16 0.19 0.59 0.07 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 96 1.06 0.20 0.35 0.06 0.6




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 737 1.62 0.22 0.50 0.05 0.5
Derivatized - MS/MS PE NeoGram Kit 120 3.91 0.33 1.05 0.07 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 93 1.89 0.43 0.65 0.06 0.6
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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MALONYLCARNITINE (μmol C3DC/L blood)




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 803 0.03 0.02 0.03 0.03 0.6
Derivatized - MS/MS PE NeoGram Kit 82 0.03 0.01 0.02 0.01 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 123 0.03 0.02 0.03 0.02 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 808 0.33 0.06 0.12 0.03 0.6
Derivatized - MS/MS PE NeoGram Kit 86 0.70 0.08 0.15 0.01 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 123 0.35 0.07 0.12 0.02 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 815 0.92 0.13 0.32 0.03 0.6
Derivatized - MS/MS PE NeoGram Kit 88 1.93 0.20 0.47 0.01 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 124 1.00 0.17 0.35 0.02 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 811 1.83 0.25 0.59 0.03 0.6
Derivatized - MS/MS PE NeoGram Kit 86 4.03 0.43 0.88 0.01 1.3
Derivatized - MS/MS Chromsystems MassChrom Kit 124 2.01 0.35 0.67 0.02 0.7
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201682
Table 17t. 2015 Quality Control Data Summaries of Statistical Analyses 
MALONYLCARNITINE + HYDROXYBUTYRYLCARNITINE 
(μmol C3DC+C4OH/L blood)




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 119 0.09 0.02 0.05 0.09 0.4
Non-derivatized - MS/MS PE NeoBase Kit 493 0.06 0.01 0.03 0.05 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 48 0.12 0.04 0.15 0.08 0.6




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 118 0.55 0.08 0.26 0.09 0.4
Non-derivatized - MS/MS PE NeoBase Kit 479 0.39 0.04 0.11 0.05 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 50 0.78 0.14 0.88 0.08 0.6




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 120 1.17 0.17 0.63 0.09 0.4
Non-derivatized - MS/MS PE NeoBase Kit 473 0.79 0.07 0.20 0.05 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 50 1.51 0.19 1.81 0.08 0.6




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 120 2.50 0.31 1.35 0.09 0.4
Non-derivatized - MS/MS PE NeoBase Kit 479 1.78 0.14 0.41 0.05 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 50 3.65 0.70 4.33 0.08 0.6
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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MALONYLCARNITINE + HYDROXYBUTYRYLCARNITINE 
(μmol C3DC+C4OH/L blood)




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 139 0.08 0.02 0.05 0.08 0.5
Non-derivatized - MS/MS PE NeoBase Kit 521 0.05 0.01 0.02 0.04 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 70 0.09 0.04 0.12 0.16 0.3




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 136 0.60 0.09 0.34 0.08 0.5
Non-derivatized - MS/MS PE NeoBase Kit 531 0.39 0.03 0.14 0.04 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 65 0.49 0.04 0.76 0.16 0.3




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 137 1.21 0.19 0.69 0.08 0.5
Non-derivatized - MS/MS PE NeoBase Kit 510 0.79 0.06 0.14 0.04 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 63 0.86 0.12 1.54 0.16 0.3




Lab SD Total SD Y- Intercept* Slope
Non-derivatized - MS/MS non-kit 134 2.73 0.32 1.52 0.08 0.5
Non-derivatized - MS/MS PE NeoBase Kit 509 1.83 0.12 0.30 0.04 0.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 60 1.60 0.25 0.43 0.16 0.3
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201684
Table 17u. 2015 Quality Control Data Summaries of Statistical Analyses 
BUTYRYLCARNITINE (μmol C4/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 803 0.14 0.03 0.05 0.14 0.8
Non-derivatized - MS/MS non-kit 173 0.13 0.02 0.02 0.14 0.8
Derivatized - MS/MS PE NeoGram Kit 122 0.15 0.04 0.04 0.13 0.7
Non-derivatized - MS/MS PE NeoBase Kit 621 0.13 0.02 0.04 0.12 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 101 0.14 0.05 0.09 0.11 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 0.12 0.02 0.04 0.11 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 0.13 0.01 0.01 0.14 0.9
Lot 1466 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 814 0.97 0.12 0.18 0.14 0.8
Non-derivatized - MS/MS non-kit 168 1.00 0.10 0.12 0.14 0.8
Derivatized - MS/MS PE NeoGram Kit 129 0.85 0.13 0.15 0.13 0.7
Non-derivatized - MS/MS PE NeoBase Kit 621 0.90 0.06 0.11 0.12 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 108 0.88 0.13 0.18 0.11 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.89 0.09 0.14 0.11 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 1.01 0.06 0.06 0.14 0.9
Lot 1467 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 812 2.16 0.22 0.35 0.14 0.8
Non-derivatized - MS/MS non-kit 168 2.24 0.22 0.27 0.14 0.8
Derivatized - MS/MS PE NeoGram Kit 127 1.94 0.23 0.29 0.13 0.7
Non-derivatized - MS/MS PE NeoBase Kit 627 2.05 0.14 0.24 0.12 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 1.84 0.24 0.34 0.11 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 1.92 0.18 0.30 0.11 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 2.31 0.14 0.15 0.14 0.9
Lot 1468 - Enriched 5.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 833 4.23 0.43 0.68 0.14 0.8
Non-derivatized - MS/MS non-kit 178 4.32 0.40 0.71 0.14 0.8
Derivatized - MS/MS PE NeoGram Kit 127 3.78 0.45 0.52 0.13 0.7
Non-derivatized - MS/MS PE NeoBase Kit 629 4.05 0.30 0.48 0.12 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 3.84 0.40 0.69 0.11 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 3.90 0.35 0.45 0.11 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 28 4.43 0.20 0.22 0.14 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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BUTYRYLCARNITINE (μmol C4/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 885 0.11 0.03 0.05 0.03 1.0
Non-derivatized - MS/MS non-kit 214 0.10 0.02 0.02 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 90 0.12 0.04 0.05 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 670 0.10 0.02 0.03 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 122 0.10 0.03 0.03 0.02 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 101 0.08 0.01 0.01 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.09 0.01 0.02 0.03 1.0
Lot 1562 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 884 1.00 0.12 0.18 0.03 1.0
Non-derivatized - MS/MS non-kit 227 1.00 0.10 0.16 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 99 0.87 0.16 0.17 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 674 0.92 0.07 0.11 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 128 0.85 0.11 0.15 0.02 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 104 0.87 0.06 0.08 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 1.00 0.05 0.13 0.03 1.0
Lot 1563 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 882 2.73 0.28 0.44 0.03 1.0
Non-derivatized - MS/MS non-kit 230 2.87 0.22 0.43 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 97 2.31 0.36 0.42 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 658 2.57 0.18 0.26 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 130 2.41 0.25 0.41 0.02 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 105 2.44 0.17 0.23 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 2.81 0.16 0.31 0.03 1.0
Lot 1564 - Enriched 5.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 906 4.98 0.48 0.83 0.03 1.0
Non-derivatized - MS/MS non-kit 230 5.10 0.42 0.73 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 100 4.25 0.67 0.83 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 670 4.62 0.30 0.50 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 129 4.33 0.42 0.71 0.02 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 108 4.40 0.32 0.40 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 5.00 0.27 0.58 0.03 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201686
Table 17v. 2015 Quality Control Data Summaries of Statistical Analyses 
HYDROXYBUTYRYLCARNITINE (μmol C4OH/L blood)




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 691 0.08 0.02 0.03 0.08 0.7
Derivatized - MS/MS PE NeoGram Kit 106 0.10 0.03 0.05 0.11 0.7
Derivatized - MS/MS Chromsystems MassChrom Kit 67 0.06 0.02 0.03 0.06 0.7




 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 703 0.41 0.06 0.11 0.08 0.7
Derivatized - MS/MS PE NeoGram Kit 109 0.47 0.08 0.19 0.11 0.7
Derivatized - MS/MS Chromsystems MassChrom Kit 70 0.40 0.05 0.08 0.06 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 703 0.74 0.10 0.19 0.08 0.7
Derivatized - MS/MS PE NeoGram Kit 106 0.85 0.14 0.38 0.11 0.7
Derivatized - MS/MS Chromsystems MassChrom Kit 70 0.70 0.09 0.14 0.06 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 714 1.75 0.21 0.42 0.08 0.7
Derivatized - MS/MS PE NeoGram Kit 107 1.93 0.25 0.77 0.11 0.7
Derivatized - MS/MS Chromsystems MassChrom Kit 68 1.69 0.19 0.36 0.06 0.7
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
Summary Report 87
2015 Quality Control Data Summaries of Statistical Analyses 
HYDROXYBUTYRYLCARNITINE (μmol C4OH/L blood)




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 757 0.08 0.02 0.03 0.07 0.7
Derivatized - MS/MS PE NeoGram Kit 94 0.08 0.03 0.05 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 96 0.06 0.02 0.02 0.05 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 758 0.44 0.07 0.12 0.07 0.7
Derivatized - MS/MS PE NeoGram Kit 99 0.45 0.09 0.14 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 96 0.36 0.05 0.08 0.05 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 756 0.81 0.11 0.21 0.07 0.7
Derivatized - MS/MS PE NeoGram Kit 100 0.83 0.14 0.27 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 98 0.72 0.10 0.15 0.05 0.7




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 754 1.92 0.23 0.48 0.07 0.7
Derivatized - MS/MS PE NeoGram Kit 99 2.02 0.35 0.67 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 95 1.70 0.17 0.31 0.05 0.7
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201688
Table 17w. 2015 Quality Control Data Summaries of Statistical Analyses 
ISOVALERYLCARNITINE (μmol C5/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 846 0.09 0.02 0.03 0.10 0.8
Non-derivatized - MS/MS non-kit 232 0.08 0.01 0.02 0.09 0.9
Derivatized - MS/MS PE NeoGram Kit 127 0.08 0.02 0.03 0.08 0.8
Non-derivatized - MS/MS PE NeoBase Kit 638 0.07 0.01 0.01 0.08 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 113 0.10 0.03 0.05 0.10 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 86 0.07 0.01 0.03 0.07 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 0.08 0.01 0.02 0.09 0.9
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 848 0.53 0.06 0.10 0.10 0.8
Non-derivatized - MS/MS non-kit 246 0.56 0.05 0.07 0.09 0.9
Derivatized - MS/MS PE NeoGram Kit 126 0.49 0.07 0.08 0.08 0.8
Non-derivatized - MS/MS PE NeoBase Kit 635 0.52 0.04 0.07 0.08 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 118 0.56 0.07 0.12 0.10 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.50 0.05 0.10 0.07 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 0.58 0.04 0.05 0.09 0.9
Lot 1467 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 846 1.32 0.14 0.23 0.10 0.8
Non-derivatized - MS/MS non-kit 243 1.40 0.11 0.17 0.09 0.9
Derivatized - MS/MS PE NeoGram Kit 127 1.23 0.15 0.19 0.08 0.8
Non-derivatized - MS/MS PE NeoBase Kit 638 1.31 0.09 0.16 0.08 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 115 1.35 0.18 0.24 0.10 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 1.19 0.11 0.22 0.07 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 1.46 0.07 0.10 0.09 0.9
Lot 1466 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 851 2.59 0.25 0.42 0.10 0.8
Non-derivatized - MS/MS non-kit 245 2.77 0.20 0.31 0.09 0.9
Derivatized - MS/MS PE NeoGram Kit 128 2.47 0.25 0.36 0.08 0.8
Non-derivatized - MS/MS PE NeoBase Kit 638 2.59 0.18 0.31 0.08 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 119 2.71 0.31 0.44 0.10 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 2.44 0.19 0.44 0.07 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 2.88 0.15 0.22 0.09 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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ISOVALERYLCARNITINE (μmol C5/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 913 0.07 0.02 0.03 0.07 0.9
Non-derivatized - MS/MS non-kit 289 0.06 0.01 0.02 0.06 0.9
Derivatized - MS/MS PE NeoGram Kit 107 0.07 0.02 0.02 0.07 0.8
Non-derivatized - MS/MS PE NeoBase Kit 685 0.06 0.01 0.02 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 126 0.07 0.02 0.03 0.06 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 113 0.06 0.01 0.01 0.06 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 0.06 0.01 0.01 0.06 1.0
Lot 1562 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 906 0.52 0.07 0.10 0.07 0.9
Non-derivatized - MS/MS non-kit 297 0.52 0.05 0.09 0.06 0.9
Derivatized - MS/MS PE NeoGram Kit 105 0.45 0.07 0.08 0.07 0.8
Non-derivatized - MS/MS PE NeoBase Kit 687 0.48 0.04 0.06 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 123 0.51 0.08 0.10 0.06 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 117 0.49 0.05 0.07 0.06 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 0.54 0.02 0.04 0.06 1.0
Lot 1563 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 904 1.36 0.15 0.24 0.07 0.9
Non-derivatized - MS/MS non-kit 288 1.47 0.12 0.23 0.06 0.9
Derivatized - MS/MS PE NeoGram Kit 110 1.23 0.17 0.23 0.07 0.8
Non-derivatized - MS/MS PE NeoBase Kit 686 1.31 0.10 0.17 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 127 1.35 0.14 0.19 0.06 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 117 1.34 0.09 0.23 0.06 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 1.47 0.06 0.10 0.06 1.0
Lot 1564 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 911 2.67 0.27 0.46 0.07 0.9
Non-derivatized - MS/MS non-kit 285 2.84 0.20 0.42 0.06 0.9
Derivatized - MS/MS PE NeoGram Kit 107 2.38 0.37 0.42 0.07 0.8
Non-derivatized - MS/MS PE NeoBase Kit 689 2.57 0.17 0.28 0.06 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 128 2.72 0.31 0.49 0.06 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 117 2.64 0.17 0.40 0.06 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 2.91 0.18 0.28 0.06 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201690
Table 17x. 2015 Quality Control Data Summaries of Statistical Analyses 
GLUTARYLCARNITINE (μmol C5DC/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 843 0.02 0.01 0.02 0.03 0.7
Non-derivatized - MS/MS non-kit 229 0.04 0.01 0.02 0.07 1.0
Derivatized - MS/MS PE NeoGram Kit 117 0.03 0.01 0.01 0.04 1.0
Non-derivatized - MS/MS PE NeoBase Kit 562 0.05 0.01 0.02 0.07 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 101 0.04 0.02 0.05 0.02 1.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 83 0.06 0.03 0.04 0.08 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 56 0.07 0.01 0.01 0.08 1.1
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 840 0.36 0.07 0.15 0.03 0.7
Non-derivatized - MS/MS non-kit 240 0.55 0.06 0.16 0.07 1.0
Derivatized - MS/MS PE NeoGram Kit 120 0.52 0.05 0.06 0.04 1.0
Non-derivatized - MS/MS PE NeoBase Kit 569 0.57 0.05 0.07 0.07 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 107 0.65 0.13 0.27 0.02 1.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.71 0.09 0.21 0.08 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 0.62 0.05 0.05 0.08 1.1
Lot 1467 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 840 0.70 0.12 0.31 0.03 0.7
Non-derivatized - MS/MS non-kit 236 1.05 0.11 0.31 0.07 1.0
Derivatized - MS/MS PE NeoGram Kit 123 1.04 0.09 0.14 0.04 1.0
Non-derivatized - MS/MS PE NeoBase Kit 585 1.10 0.09 0.15 0.07 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 109 1.25 0.28 0.53 0.02 1.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 1.36 0.25 0.46 0.08 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 1.16 0.07 0.08 0.08 1.1
Lot 1468 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 840 1.65 0.25 0.72 0.03 0.7
Non-derivatized - MS/MS non-kit 236 2.45 0.23 0.72 0.07 1.0
Derivatized - MS/MS PE NeoGram Kit 124 2.48 0.20 0.26 0.04 1.0
Non-derivatized - MS/MS PE NeoBase Kit 590 2.58 0.21 0.34 0.07 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 109 3.16 0.44 1.34 0.02 1.3
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 3.21 0.44 1.06 0.08 1.3
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 2.74 0.19 0.20 0.08 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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GLUTARYLCARNITINE (μmol C5DC/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 881 0.02 0.01 0.02 0.02 0.6
Non-derivatized - MS/MS non-kit 286 0.04 0.01 0.03 0.05 0.9
Derivatized - MS/MS PE NeoGram Kit 102 0.03 0.01 0.02 0.02 1.1
Non-derivatized - MS/MS PE NeoBase Kit 632 0.05 0.01 0.02 0.04 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 125 0.04 0.02 0.03 0.06 1.4
Non-derivatized - MS/MS Chromsystems MassChrom Kit 112 0.07 0.03 0.05 0.07 1.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 0.06 0.01 0.01 0.06 1.2
Lot 1562 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 883 0.34 0.06 0.14 0.02 0.6
Non-derivatized - MS/MS non-kit 281 0.54 0.07 0.18 0.05 0.9
Derivatized - MS/MS PE NeoGram Kit 105 0.56 0.07 0.09 0.02 1.1
Non-derivatized - MS/MS PE NeoBase Kit 628 0.56 0.05 0.09 0.04 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 128 0.75 0.18 0.28 0.06 1.4
Non-derivatized - MS/MS Chromsystems MassChrom Kit 116 0.91 0.15 0.30 0.07 1.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 0.64 0.04 0.05 0.06 1.2
Lot 1563 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 882 0.63 0.09 0.26 0.02 0.6
Non-derivatized - MS/MS non-kit 278 0.97 0.11 0.35 0.05 0.9
Derivatized - MS/MS PE NeoGram Kit 107 1.05 0.11 0.14 0.02 1.1
Non-derivatized - MS/MS PE NeoBase Kit 645 1.05 0.09 0.18 0.04 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 129 1.41 0.22 0.47 0.06 1.4
Non-derivatized - MS/MS Chromsystems MassChrom Kit 113 1.63 0.21 0.47 0.07 1.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 47 1.20 0.07 0.09 0.06 1.2
Lot 1564 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 875 1.59 0.21 0.63 0.02 0.6
Non-derivatized - MS/MS non-kit 277 2.40 0.24 0.86 0.05 0.9
Derivatized - MS/MS PE NeoGram Kit 105 2.64 0.30 0.39 0.02 1.1
Non-derivatized - MS/MS PE NeoBase Kit 649 2.65 0.21 0.43 0.04 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 128 3.43 0.47 1.10 0.06 1.4
Non-derivatized - MS/MS Chromsystems MassChrom Kit 114 4.10 0.37 1.22 0.07 1.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 2.94 0.19 0.32 0.06 1.2
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201692
Table 17y. 2015 Quality Control Data Summaries of Statistical Analyses 
HYDROXYISOVALERYLCARNITINE (μmol C5OH/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 833 0.39 0.06 0.10 0.39 0.8
Non-derivatized - MS/MS non-kit 199 0.55 0.05 0.10 0.56 0.8
Derivatized - MS/MS PE NeoGram Kit 125 0.36 0.07 0.08 0.36 0.7
Non-derivatized - MS/MS PE NeoBase Kit 522 0.43 0.04 0.08 0.43 0.5
Derivatized - MS/MS Chromsystems MassChrom Kit 98 0.42 0.08 0.12 0.42 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 57 0.31 0.05 0.07 0.33 0.4
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 0.66 0.05 0.09 0.63 1.0
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 819 0.77 0.09 0.16 0.39 0.8
Non-derivatized - MS/MS non-kit 199 0.97 0.08 0.19 0.56 0.8
Derivatized - MS/MS PE NeoGram Kit 129 0.70 0.10 0.14 0.36 0.7
Non-derivatized - MS/MS PE NeoBase Kit 524 0.70 0.05 0.13 0.43 0.5
Derivatized - MS/MS Chromsystems MassChrom Kit 96 0.77 0.12 0.16 0.42 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 60 0.56 0.07 0.13 0.33 0.4
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 55 1.11 0.06 0.12 0.63 1.0
Lot 1467 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 822 1.53 0.18 0.33 0.39 0.8
Non-derivatized - MS/MS non-kit 198 1.74 0.15 0.34 0.56 0.8
Derivatized - MS/MS PE NeoGram Kit 125 1.35 0.18 0.25 0.36 0.7
Non-derivatized - MS/MS PE NeoBase Kit 522 1.21 0.09 0.22 0.43 0.5
Derivatized - MS/MS Chromsystems MassChrom Kit 99 1.49 0.21 0.31 0.42 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 58 0.98 0.09 0.26 0.33 0.4
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 57 2.08 0.12 0.27 0.63 1.0
Lot 1468 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 816 2.28 0.23 0.47 0.39 0.8
Non-derivatized - MS/MS non-kit 198 2.54 0.20 0.51 0.56 0.8
Derivatized - MS/MS PE NeoGram Kit 128 2.07 0.25 0.36 0.36 0.7
Non-derivatized - MS/MS PE NeoBase Kit 526 1.75 0.13 0.32 0.43 0.5
Derivatized - MS/MS Chromsystems MassChrom Kit 99 2.17 0.26 0.48 0.42 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 56 1.36 0.16 0.26 0.33 0.4
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 58 3.11 0.14 0.37 0.63 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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HYDROXYISOVALERYLCARNITINE (μmol C5OH/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 909 0.48 0.07 0.12 0.45 0.9
Non-derivatized - MS/MS non-kit 239 0.66 0.08 0.16 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 109 0.44 0.07 0.09 0.42 0.8
Non-derivatized - MS/MS PE NeoBase Kit 525 0.50 0.05 0.10 0.49 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 138 0.44 0.06 0.12 0.44 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 80 0.44 0.10 0.18 0.40 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.73 0.04 0.06 0.70 1.1
Lot 1562 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 890 1.30 0.16 0.26 0.45 0.9
Non-derivatized - MS/MS non-kit 240 1.51 0.13 0.36 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 108 1.20 0.14 0.21 0.42 0.8
Non-derivatized - MS/MS PE NeoBase Kit 522 1.08 0.08 0.22 0.49 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 139 1.18 0.14 0.32 0.44 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 80 1.04 0.18 0.40 0.40 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 1.75 0.10 0.15 0.70 1.1




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 893 2.12 0.23 0.41 0.45 0.9
Non-derivatized - MS/MS non-kit 236 2.44 0.23 0.56 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 108 1.92 0.24 0.34 0.42 0.8
Non-derivatized - MS/MS PE NeoBase Kit 523 1.67 0.12 0.35 0.49 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 139 1.90 0.23 0.49 0.44 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 80 1.67 0.10 0.52 0.40 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 2.80 0.14 0.23 0.70 1.1
Lot 1564 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 900 3.09 0.34 0.66 0.45 0.9
Non-derivatized - MS/MS non-kit 240 3.36 0.28 0.81 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 109 2.80 0.39 0.48 0.42 0.8
Non-derivatized - MS/MS PE NeoBase Kit 519 2.30 0.14 0.45 0.49 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 137 2.66 0.32 0.77 0.44 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 79 2.42 0.21 0.79 0.40 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 3.95 0.23 0.35 0.70 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
June  201694
Table 17z. 2015 Quality Control Data Summaries of Statistical Analyses 
HEXANOYLCARNITINE (μmol C6/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 846 0.03 0.01 0.03 0.04 0.8
Non-derivatized - MS/MS non-kit 198 0.02 0.01 0.01 0.02 0.8
Derivatized - MS/MS PE NeoGram Kit 120 0.03 0.02 0.02 0.07 0.6
Non-derivatized - MS/MS PE NeoBase Kit 631 0.02 0.01 0.01 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 103 0.06 0.03 0.05 0.09 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 84 0.02 0.01 0.01 0.04 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 0.01 0.00 0.00 0.01 0.7
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 837 0.43 0.06 0.09 0.04 0.8
Non-derivatized - MS/MS non-kit 196 0.44 0.05 0.09 0.02 0.8
Derivatized - MS/MS PE NeoGram Kit 128 0.42 0.06 0.08 0.07 0.6
Non-derivatized - MS/MS PE NeoBase Kit 659 0.42 0.03 0.05 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 108 0.46 0.07 0.08 0.09 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 0.46 0.05 0.07 0.04 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 0.36 0.02 0.04 0.01 0.7
Lot 1467 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 837 0.79 0.10 0.17 0.04 0.8
Non-derivatized - MS/MS non-kit 196 0.84 0.09 0.18 0.02 0.8
Derivatized - MS/MS PE NeoGram Kit 129 0.68 0.09 0.10 0.07 0.6
Non-derivatized - MS/MS PE NeoBase Kit 649 0.80 0.06 0.09 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 0.77 0.11 0.12 0.09 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.82 0.07 0.13 0.04 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 0.69 0.04 0.10 0.01 0.7
Lot 1468 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 839 1.93 0.19 0.36 0.04 0.8
Non-derivatized - MS/MS non-kit 189 2.05 0.23 0.43 0.02 0.8
Derivatized - MS/MS PE NeoGram Kit 129 1.56 0.16 0.21 0.07 0.6
Non-derivatized - MS/MS PE NeoBase Kit 652 1.96 0.15 0.23 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 1.75 0.20 0.23 0.09 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 2.01 0.14 0.22 0.04 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 1.73 0.12 0.23 0.01 0.7
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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HEXANOYLCARNITINE (μmol C6/L blood)
Lot 1561 - Nonenriched 0 μmol/L whole blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 881 0.03 0.01 0.02 0.04 0.8
Non-derivatized - MS/MS non-kit 228 0.01 0.00 0.01 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 101 0.03 0.02 0.02 0.08 0.6
Non-derivatized - MS/MS PE NeoBase Kit 692 0.01 0.01 0.01 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 128 0.04 0.01 0.02 0.09 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 102 0.01 0.01 0.01 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 37 0.01 0.00 0.00 0.03 0.8
Lot 1562 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 901 0.48 0.06 0.11 0.04 0.8
Non-derivatized - MS/MS non-kit 236 0.47 0.05 0.09 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 106 0.41 0.07 0.08 0.08 0.6
Non-derivatized - MS/MS PE NeoBase Kit 716 0.46 0.04 0.05 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 129 0.45 0.07 0.07 0.09 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 109 0.48 0.03 0.05 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.45 0.03 0.05 0.03 0.8
Lot 1563 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 894 0.86 0.10 0.18 0.04 0.8
Non-derivatized - MS/MS non-kit 239 0.87 0.09 0.16 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 107 0.66 0.09 0.14 0.08 0.6
Non-derivatized - MS/MS PE NeoBase Kit 703 0.83 0.05 0.09 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 125 0.72 0.08 0.10 0.09 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 0.86 0.06 0.09 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.82 0.06 0.12 0.03 0.8
Lot 1562 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 896 2.14 0.23 0.45 0.04 0.8
Non-derivatized - MS/MS non-kit 239 2.18 0.19 0.40 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 107 1.46 0.17 0.28 0.08 0.6
Non-derivatized - MS/MS PE NeoBase Kit 706 2.04 0.12 0.20 0.03 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 126 1.61 0.21 0.35 0.09 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 110 2.18 0.15 0.32 0.02 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 2.02 0.14 0.30 0.03 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17aa. 2015 Quality Control Data Summaries of Statistical Analyses 
OCTANOYLCARNITINE (μmol C8/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 865 0.03 0.01 0.02 0.03 0.9
Non-derivatized - MS/MS non-kit 260 0.02 0.01 0.01 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 119 0.02 0.02 0.02 0.01 0.9
Non-derivatized - MS/MS PE NeoBase Kit 643 0.02 0.01 0.01 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 101 0.03 0.02 0.04 0.03 0.8
Non-derivatized - MS/MSChromsystems MassChrom Kit 88 0.02 0.01 0.01 0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 56 0.03 0.01 0.01 0.02 1.0
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 856 0.50 0.06 0.11 0.03 0.9
Non-derivatized - MS/MS non-kit 262 0.50 0.04 0.07 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 125 0.45 0.08 0.09 0.01 0.9
Non-derivatized - MS/MS PE NeoBase Kit 640 0.47 0.04 0.06 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 105 0.45 0.07 0.08 0.03 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 0.42 0.04 0.06 0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 0.51 0.04 0.05 0.02 1.0




Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 857 0.95 0.12 0.19 0.03 0.9
Non-derivatized - MS/MS non-kit 266 0.98 0.09 0.15 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 126 0.86 0.12 0.14 0.01 0.9
Non-derivatized - MS/MS PE NeoBase Kit 644 0.92 0.07 0.10 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 108 0.86 0.11 0.13 0.03 0.8
Non-derivatized - MS/MSChromsystems MassChrom Kit 90 0.78 0.06 0.10 0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 0.99 0.06 0.09 0.02 1.0
Lot 1468 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 858 2.35 0.25 0.41 0.03 0.9
Non-derivatized - MS/MS non-kit 267 2.45 0.20 0.33 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 129 2.21 0.25 0.33 0.01 0.9
Non-derivatized - MS/MS PE NeoBase Kit 642 2.35 0.17 0.26 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 107 2.12 0.23 0.30 0.03 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 2.04 0.16 0.24 0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 59 2.51 0.15 0.17 0.02 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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OCTANOYLCARNITINE (μmol C8/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 909 0.03 0.01 0.02 0.03 1.0
Non-derivatized - MS/MS non-kit 305 0.02 0.01 0.01 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 104 0.02 0.01 0.02 0.03 0.9
Non-derivatized - MS/MS PE NeoBase Kit 711 0.01 0.01 0.01 0.01 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 128 0.02 0.01 0.01 0.03 0.9
Non-derivatized - MS/MSChromsystems MassChrom Kit 115 0.02 0.01 0.01 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.02 0.01 0.01 0.02 1.1
Lot 1562 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 898 0.57 0.07 0.11 0.03 1.0
Non-derivatized - MS/MS non-kit 315 0.54 0.05 0.07 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 105 0.51 0.08 0.09 0.03 0.9
Non-derivatized - MS/MS PE NeoBase Kit 700 0.52 0.04 0.05 0.01 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 124 0.48 0.06 0.07 0.03 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 118 0.47 0.03 0.05 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.61 0.03 0.09 0.02 1.1
Lot 1563 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 889 1.05 0.12 0.18 0.03 1.0
Non-derivatized - MS/MS non-kit 304 1.04 0.09 0.13 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 110 0.94 0.14 0.17 0.03 0.9
Non-derivatized - MS/MS PE NeoBase Kit 701 0.98 0.07 0.10 0.01 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 123 0.89 0.10 0.12 0.03 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 117 0.89 0.06 0.10 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 1.14 0.07 0.18 0.02 1.1
Lot 1564 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 889 2.61 0.25 0.41 0.03 1.0
Non-derivatized - MS/MS non-kit 307 2.61 0.19 0.28 0.02 1.0
Derivatized - MS/MS PE NeoGram Kit 110 2.34 0.35 0.39 0.03 0.9
Non-derivatized - MS/MS PE NeoBase Kit 712 2.48 0.14 0.24 0.01 1.0
Derivatized - MS/MS Chromsystems MassChrom Kit 125 2.17 0.21 0.29 0.03 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 120 2.27 0.15 0.26 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 2.87 0.19 0.45 0.02 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17bb. 2015 Quality Control Data Summaries of Statistical Analyses 
DECANOYLCARNITINE (μmol C10/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 813 0.02 0.01 0.02 0.00 1.0
Non-derivatized - MS/MS non-kit 245 0.02 0.01 0.01 0.00 1.0
Derivatized - MS/MS PE NeoGram Kit 124 0.02 0.01 0.02 0.00 0.7
Non-derivatized - MS/MS PE NeoBase Kit 649 0.02 0.01 0.01 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 97 0.02 0.01 0.02 0.00 0.7
Non-derivatized - MS/MSChromsystems MassChrom Kit 85 0.02 0.01 0.01 -0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 57 0.02 0.01 0.01 -0.01 1.1
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 833 0.48 0.07 0.12 0.00 1.0
Non-derivatized - MS/MS non-kit 246 0.52 0.04 0.09 0.00 1.0
Derivatized - MS/MS PE NeoGram Kit 127 0.37 0.06 0.07 0.00 0.7
Non-derivatized - MS/MS PE NeoBase Kit 644 0.42 0.04 0.06 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 105 0.38 0.06 0.08 0.00 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 0.38 0.04 0.05 -0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 0.55 0.04 0.12 -0.01 1.1
Lot 1467 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 829 0.93 0.13 0.22 0.00 1.0
Non-derivatized - MS/MS non-kit 244 0.98 0.10 0.19 0.00 1.0
Derivatized - MS/MS PE NeoGram Kit 128 0.72 0.11 0.13 0.00 0.7
Non-derivatized - MS/MS PE NeoBase Kit 650 0.81 0.07 0.10 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 107 0.70 0.10 0.14 0.00 0.7
Non-derivatized - MS/MSChromsystems MassChrom Kit 86 0.71 0.06 0.11 -0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 1.06 0.08 0.18 -0.01 1.1
Lot 1468 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 836 2.40 0.29 0.53 0.00 1.0
Non-derivatized - MS/MS non-kit 248 2.58 0.23 0.48 0.00 1.0
Derivatized - MS/MS PE NeoGram Kit 126 1.86 0.20 0.28 0.00 0.7
Non-derivatized - MS/MS PE NeoBase Kit 638 2.15 0.15 0.26 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 107 1.86 0.23 0.33 0.00 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 1.94 0.14 0.23 -0.01 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 60 2.78 0.21 0.39 -0.01 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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DECANOYLCARNITINE (μmol C10/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 872 0.02 0.01 0.02 0.02 1.0
Non-derivatized - MS/MS non-kit 284 0.02 0.01 0.02 0.02 1.1
Derivatized - MS/MS PE NeoGram Kit 108 0.03 0.02 0.03 0.02 0.8
Non-derivatized - MS/MS PE NeoBase Kit 715 0.02 0.01 0.01 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 127 0.03 0.01 0.02 0.03 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 116 0.02 0.01 0.01 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 0.02 0.00 0.01 0.01 1.3
Lot 1562 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 876 0.55 0.07 0.12 0.02 1.0
Non-derivatized - MS/MS non-kit 294 0.59 0.06 0.09 0.02 1.1
Derivatized - MS/MS PE NeoGram Kit 106 0.42 0.07 0.08 0.02 0.8
Non-derivatized - MS/MS PE NeoBase Kit 700 0.47 0.04 0.06 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 125 0.37 0.05 0.08 0.03 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 115 0.45 0.05 0.09 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.63 0.06 0.11 0.01 1.3
Lot 1563 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 881 1.07 0.14 0.22 0.02 1.0
Non-derivatized - MS/MS non-kit 283 1.16 0.11 0.17 0.02 1.1
Derivatized - MS/MS PE NeoGram Kit 106 0.79 0.11 0.15 0.02 0.8
Non-derivatized - MS/MS PE NeoBase Kit 716 0.92 0.06 0.11 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 125 0.75 0.09 0.16 0.03 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 117 0.92 0.08 0.20 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 1.27 0.11 0.21 0.01 1.3
Lot 1564 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 884 2.63 0.28 0.52 0.02 1.0
Non-derivatized - MS/MS non-kit 280 2.87 0.22 0.38 0.02 1.1
Derivatized - MS/MS PE NeoGram Kit 107 2.04 0.28 0.34 0.02 0.8
Non-derivatized - MS/MS PE NeoBase Kit 718 2.34 0.15 0.26 0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 124 1.76 0.17 0.34 0.03 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 117 2.25 0.16 0.44 0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 3.14 0.28 0.54 0.01 1.3
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17cc. 2015 Quality Control Data  Summaries of Statistical Analyses 
DODECANOYLCARNITINE (μmol C12/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 745 0.03 0.02 0.03 0.05 0.9
Non-derivatized - MS/MS non-kit 162 0.01 0.00 0.01 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 128 0.03 0.02 0.02 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 595 0.01 0.00 0.00 0.00 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 105 0.07 0.03 0.06 0.11 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 85 0.01 0.01 0.01 0.00 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.01 0.00 0.00 0.02 0.9
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 761 0.48 0.09 0.14 0.05 0.9
Non-derivatized - MS/MS non-kit 161 0.45 0.04 0.09 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 125 0.45 0.07 0.09 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 604 0.41 0.04 0.05 0.00 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 104 0.51 0.09 0.14 0.11 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 0.38 0.04 0.05 0.00 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.48 0.04 0.07 0.02 0.9
Lot 1467 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 756 0.94 0.15 0.26 0.05 0.9
Non-derivatized - MS/MS non-kit 158 0.87 0.09 0.17 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 127 0.89 0.11 0.17 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 616 0.80 0.07 0.09 0.00 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 105 1.05 0.19 0.33 0.11 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 0.71 0.06 0.13 0.00 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.96 0.09 0.11 0.02 0.9
Lot 1468 - Enriched 2.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 773 2.22 0.29 0.53 0.05 0.9
Non-derivatized - MS/MS non-kit 160 2.14 0.23 0.43 0.02 0.9
Derivatized - MS/MS PE NeoGram Kit 125 2.09 0.24 0.30 0.04 0.8
Non-derivatized - MS/MS PE NeoBase Kit 609 2.04 0.15 0.22 0.00 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 102 2.20 0.25 0.41 0.11 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 1.84 0.12 0.18 0.00 0.7
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 2.31 0.21 0.21 0.02 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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DODECANOYLCARNITINE (μmol C12/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 780 0.03 0.01 0.03 0.02 1.0
Non-derivatized - MS/MS non-kit 202 0.01 0.00 0.01 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 100 0.04 0.02 0.03 0.02 0.9
Non-derivatized - MS/MS PE NeoBase Kit 650 0.01 0.00 0.01 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 124 0.05 0.02 0.03 0.04 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 106 0.01 0.00 0.01 -0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 36 0.01 0.00 0.00 0.00 1.1
Lot 1562 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 791 0.98 0.14 0.25 0.02 1.0
Non-derivatized - MS/MS non-kit 190 1.01 0.12 0.22 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 99 0.94 0.14 0.15 0.02 0.9
Non-derivatized - MS/MS PE NeoBase Kit 669 0.92 0.06 0.09 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 125 0.95 0.11 0.22 0.04 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 104 0.85 0.06 0.09 -0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 39 1.06 0.06 0.13 0.00 1.1
Lot 1563 - Enriched 2.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 793 1.89 0.23 0.46 0.02 1.0
Non-derivatized - MS/MS non-kit 190 2.02 0.22 0.49 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 100 1.83 0.25 0.30 0.02 0.9
Non-derivatized - MS/MS PE NeoBase Kit 659 1.82 0.11 0.16 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 124 1.82 0.16 0.32 0.04 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 106 1.68 0.13 0.21 -0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 2.13 0.15 0.29 0.00 1.1
Lot 1564 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 792 2.94 0.35 0.68 0.02 1.0
Non-derivatized - MS/MS non-kit 190 3.01 0.29 0.62 0.01 1.0
Derivatized - MS/MS PE NeoGram Kit 98 2.81 0.39 0.43 0.02 0.9
Non-derivatized - MS/MS PE NeoBase Kit 667 2.83 0.18 0.26 -0.01 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 122 2.78 0.29 0.48 0.04 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 105 2.62 0.18 0.27 -0.01 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 3.24 0.19 0.46 0.00 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17dd. 2015 Quality Control Data Summaries of Statistical Analyses 
MYRISTOYLCARNITINE (μmol C14/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 819 0.06 0.02 0.03 0.05 1.0
Non-derivatized - MS/MS non-kit 175 0.04 0.01 0.01 0.03 1.0
Derivatized - MS/MS PE NeoGram Kit 126 0.06 0.02 0.02 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 622 0.04 0.01 0.01 0.02 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 113 0.08 0.03 0.05 0.08 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 86 0.03 0.01 0.01 0.02 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 28 0.04 0.00 0.00 0.01 1.1
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 820 0.53 0.07 0.10 0.05 1.0
Non-derivatized - MS/MS non-kit 179 0.53 0.05 0.07 0.03 1.0
Derivatized - MS/MS PE NeoGram Kit 125 0.50 0.07 0.08 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 628 0.48 0.04 0.05 0.02 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 0.49 0.08 0.08 0.08 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.43 0.04 0.08 0.02 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 0.54 0.03 0.04 0.01 1.1
Lot 1467 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 826 1.47 0.17 0.27 0.05 1.0
Non-derivatized - MS/MS non-kit 180 1.49 0.14 0.23 0.03 1.0
Derivatized - MS/MS PE NeoGram Kit 128 1.36 0.15 0.20 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 635 1.40 0.10 0.15 0.02 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 119 1.30 0.17 0.19 0.08 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 1.22 0.09 0.20 0.02 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 1.62 0.12 0.13 0.01 1.1
Lot 1468 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 824 2.94 0.34 0.51 0.05 1.0
Non-derivatized - MS/MS non-kit 179 3.02 0.26 0.44 0.03 1.0
Derivatized - MS/MS PE NeoGram Kit 127 2.73 0.28 0.41 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 626 2.81 0.20 0.30 0.02 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 114 2.54 0.25 0.34 0.08 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 2.51 0.14 0.34 0.02 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 30 3.30 0.29 0.30 0.01 1.1
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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MYRISTOYLCARNITINE (μmol C14/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 870 0.06 0.02 0.03 0.06 1.0
Non-derivatized - MS/MS non-kit 226 0.05 0.01 0.01 0.04 1.0
Derivatized - MS/MS PE NeoGram Kit 108 0.07 0.02 0.02 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 684 0.04 0.01 0.01 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 0.07 0.02 0.03 0.07 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 0.03 0.01 0.01 0.03 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 0.04 0.01 0.01 0.04 1.0
Lot 1562 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 872 0.56 0.07 0.11 0.06 1.0
Non-derivatized - MS/MS non-kit 235 0.55 0.05 0.10 0.04 1.0
Derivatized - MS/MS PE NeoGram Kit 109 0.50 0.09 0.10 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 688 0.48 0.04 0.06 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 125 0.47 0.05 0.08 0.07 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 0.44 0.03 0.04 0.03 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 39 0.54 0.03 0.04 0.04 1.0
Lot 1563 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 868 1.52 0.18 0.26 0.06 1.0
Non-derivatized - MS/MS non-kit 230 1.57 0.14 0.30 0.04 1.0
Derivatized - MS/MS PE NeoGram Kit 108 1.33 0.16 0.21 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 674 1.38 0.09 0.13 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 129 1.18 0.12 0.24 0.07 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 1.27 0.08 0.12 0.03 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 1.56 0.11 0.15 0.04 1.0
Lot 1564 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 866 3.00 0.31 0.50 0.06 1.0
Non-derivatized - MS/MS non-kit 233 3.10 0.26 0.51 0.04 1.0
Derivatized - MS/MS PE NeoGram Kit 107 2.76 0.27 0.37 0.05 0.9
Non-derivatized - MS/MS PE NeoBase Kit 685 2.76 0.17 0.25 0.03 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 118 2.34 0.21 0.31 0.07 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 106 2.52 0.17 0.25 0.03 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 40 3.06 0.19 0.32 0.04 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17ee. 2015 Quality Control Data Summaries of Statistical Analyses 
PALMITOYLCARNITINE (μmol C16/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 845 0.79 0.10 0.15 0.86 0.9
Non-derivatized - MS/MS non-kit 196 0.81 0.07 0.13 0.87 0.9
Derivatized - MS/MS PE NeoGram Kit 130 0.74 0.10 0.13 0.73 0.8
Non-derivatized - MS/MS PE NeoBase Kit 654 0.72 0.06 0.08 0.76 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 106 0.81 0.11 0.15 0.87 0.8
Non-derivatized - MS/MSChromsystems MassChrom Kit 89 0.70 0.06 0.09 0.74 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.86 0.06 0.11 0.92 0.9
Lot 1466 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 858 3.44 0.33 0.45 0.86 0.9
Non-derivatized - MS/MS non-kit 199 3.64 0.30 0.56 0.87 0.9
Derivatized - MS/MS PE NeoGram Kit 124 3.07 0.29 0.41 0.73 0.8
Non-derivatized - MS/MS PE NeoBase Kit 656 3.27 0.23 0.34 0.76 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 106 3.44 0.33 0.42 0.87 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 3.28 0.26 0.40 0.74 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 3.66 0.25 0.35 0.92 0.9
Lot 1467 - Enriched 8.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 864 7.81 0.77 1.13 0.86 0.9
Non-derivatized - MS/MS non-kit 197 8.25 0.76 1.19 0.87 0.9
Derivatized - MS/MS PE NeoGram Kit 126 7.27 0.69 0.96 0.73 0.8
Non-derivatized - MS/MS PE NeoBase Kit 650 7.55 0.55 0.77 0.76 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 109 7.68 0.74 1.04 0.87 0.8
Non-derivatized - MS/MSChromsystems MassChrom Kit 85 7.41 0.53 0.62 0.74 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 8.34 0.55 0.70 0.92 0.9
Lot 1468 - Enriched 12.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 860 11.00 0.99 1.51 0.86 0.9
Non-derivatized - MS/MS non-kit 200 11.70 0.87 1.69 0.87 0.9
Derivatized - MS/MS PE NeoGram Kit 129 10.27 0.97 1.42 0.73 0.8
Non-derivatized - MS/MS PE NeoBase Kit 653 10.68 0.75 1.10 0.76 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 107 10.93 0.99 1.23 0.87 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 10.72 0.73 1.01 0.74 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 11.75 0.84 1.21 0.92 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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PALMITOYLCARNITINE (μmol C16/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 921 0.74 0.09 0.13 0.72 0.9
Non-derivatized - MS/MS non-kit 244 0.75 0.07 0.11 0.73 0.9
Derivatized - MS/MS PE NeoGram Kit 108 0.63 0.10 0.11 0.60 0.8
Non-derivatized - MS/MS PE NeoBase Kit 702 0.65 0.05 0.07 0.57 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 126 0.69 0.08 0.11 0.62 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 109 0.64 0.05 0.07 0.63 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 0.75 0.04 0.05 0.71 1.0
Lot 1562 - Enriched 4.0 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 925 4.28 0.41 0.61 0.72 0.9
Non-derivatized - MS/MS non-kit 249 4.45 0.37 0.70 0.73 0.9
Derivatized - MS/MS PE NeoGram Kit 109 3.76 0.45 0.58 0.60 0.8
Non-derivatized - MS/MS PE NeoBase Kit 709 3.91 0.25 0.36 0.57 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 128 3.96 0.35 0.46 0.62 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 3.93 0.22 0.33 0.63 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 49 4.60 0.25 0.36 0.71 1.0
Lot 1563 - Enriched 8.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 912 7.47 0.68 1.03 0.72 0.9
Non-derivatized - MS/MS non-kit 243 8.01 0.73 1.22 0.73 0.9
Derivatized - MS/MS PE NeoGram Kit 109 6.54 0.69 1.10 0.60 0.8
Non-derivatized - MS/MS PE NeoBase Kit 710 7.03 0.42 0.63 0.57 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 127 7.06 0.50 0.79 0.62 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 109 7.09 0.49 0.68 0.63 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 8.33 0.50 0.76 0.71 1.0
Lot 1564 - Enriched 12.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 925 11.30 1.01 1.57 0.72 0.9
Non-derivatized - MS/MS non-kit 249 11.89 0.89 1.72 0.73 0.9
Derivatized - MS/MS PE NeoGram Kit 107 10.00 1.06 1.65 0.60 0.8
Non-derivatized - MS/MS PE NeoBase Kit 705 10.78 0.64 0.96 0.57 0.8
Derivatized - MS/MS Chromsystems MassChrom Kit 127 10.77 0.78 1.21 0.62 0.8
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 10.49 0.64 0.87 0.63 0.8
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 12.44 0.74 1.14 0.71 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17ff. 2015 Quality Control Data Summaries of Statistical Analyses 
HYDROXYPALMITOYLCARNITINE (μmol C16OH/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 830 0.02 0.01 0.02 0.01 0.7
Non-derivatized - MS/MS non-kit 179 0.01 0.00 0.01 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 126 0.02 0.01 0.01 0.01 0.7
Non-derivatized - MS/MS PE NeoBase Kit 642 0.01 0.00 0.01 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 96 0.01 0.01 0.01 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 84 0.01 0.00 0.01 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 70 0.01 0.00 0.00 0.00 0.7
Lot 1466 - Enriched 0.25 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 823 0.19 0.03 0.05 0.01 0.7
Non-derivatized - MS/MS non-kit 178 0.18 0.02 0.03 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 124 0.17 0.03 0.03 0.01 0.7
Non-derivatized - MS/MS PE NeoBase Kit 627 0.15 0.01 0.02 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 98 0.19 0.04 0.07 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 86 0.17 0.04 0.07 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 70 0.16 0.01 0.05 0.00 0.7
Lot 1467 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 823 0.35 0.06 0.10 0.01 0.7
Non-derivatized - MS/MS non-kit 178 0.34 0.04 0.06 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 128 0.33 0.05 0.07 0.01 0.7
Non-derivatized - MS/MS PE NeoBase Kit 626 0.29 0.03 0.04 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 99 0.37 0.06 0.09 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 85 0.30 0.06 0.13 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 69 0.34 0.02 0.07 0.00 0.7
Lot 1468 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 828 0.70 0.09 0.18 0.01 0.7
Non-derivatized - MS/MS non-kit 183 0.70 0.09 0.14 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 130 0.67 0.09 0.14 0.01 0.7
Non-derivatized - MS/MS PE NeoBase Kit 626 0.60 0.05 0.08 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 91 0.72 0.09 0.13 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 0.65 0.09 0.25 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 70 0.69 0.05 0.14 0.00 0.7
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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HYDROXYPALMITOYLCARNITINE (μmol C16OH/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 879 0.01 0.01 0.01 0.01 0.7
Non-derivatized - MS/MS non-kit 233 0.01 0.00 0.01 0.00 0.8
Derivatized - MS/MS PE NeoGram Kit 94 0.01 0.01 0.01 0.02 0.7
Non-derivatized - MS/MS PE NeoBase Kit 718 0.01 0.00 0.01 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 123 0.01 0.01 0.01 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 93 0.00 0.00 0.00 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.00 0.00 0.00 0.00 0.8
Lot 1562 - Enriched 0.25 μmol/L blood
METHOD N Mean
Average Within 
 Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 878 0.20 0.03 0.05 0.01 0.7
Non-derivatized - MS/MS non-kit 242 0.20 0.03 0.06 0.00 0.8
Derivatized - MS/MS PE NeoGram Kit 99 0.19 0.04 0.04 0.02 0.7
Non-derivatized - MS/MS PE NeoBase Kit 696 0.16 0.02 0.03 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 121 0.19 0.03 0.05 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 99 0.15 0.01 0.05 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.21 0.02 0.06 0.00 0.8
Lot 1563 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 876 0.74 0.08 0.15 0.01 0.7
Non-derivatized - MS/MS non-kit 239 0.78 0.09 0.23 0.00 0.8
Derivatized - MS/MS PE NeoGram Kit 100 0.68 0.09 0.12 0.02 0.7
Non-derivatized - MS/MS PE NeoBase Kit 710 0.62 0.04 0.08 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 118 0.71 0.07 0.12 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 93 0.56 0.04 0.14 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 0.80 0.05 0.26 0.00 0.8
Lot 1564 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 884 1.13 0.12 0.24 0.01 0.7
Non-derivatized - MS/MS non-kit 237 1.18 0.13 0.33 0.00 0.8
Derivatized - MS/MS PE NeoGram Kit 98 1.04 0.16 0.23 0.02 0.7
Non-derivatized - MS/MS PE NeoBase Kit 704 0.94 0.07 0.12 0.01 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 116 1.06 0.13 0.20 0.01 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 94 0.88 0.07 0.25 0.00 0.6
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 1.21 0.08 0.39 0.00 0.8
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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STEAROYLCARNITINE (μmol C18/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 796 0.64 0.08 0.13 0.67 0.9
Non-derivatized - MS/MS non-kit 157 0.64 0.06 0.08 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 119 0.63 0.08 0.11 0.63 0.9
Non-derivatized - MS/MS PE NeoBase Kit 646 0.63 0.05 0.06 0.64 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 104 0.65 0.09 0.11 0.65 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 0.59 0.06 0.13 0.60 0.9
Lot 1466 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 810 1.54 0.18 0.29 0.67 0.9
Non-derivatized - MS/MS non-kit 158 1.56 0.14 0.21 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 117 1.49 0.15 0.19 0.63 0.9
Non-derivatized - MS/MS PE NeoBase Kit 646 1.57 0.11 0.14 0.64 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 108 1.52 0.22 0.29 0.65 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 1.44 0.14 0.31 0.60 0.9
Lot 1467 - Enriched 2.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 811 2.42 0.26 0.44 0.67 0.9
Non-derivatized - MS/MS non-kit 154 2.46 0.22 0.32 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 118 2.44 0.24 0.34 0.63 0.9
Non-derivatized - MS/MS PE NeoBase Kit 656 2.52 0.18 0.25 0.64 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 107 2.42 0.29 0.39 0.65 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 2.32 0.21 0.47 0.60 0.9
Lot 1468 - Enriched 5.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 804 4.97 0.50 0.88 0.67 0.9
Non-derivatized - MS/MS non-kit 154 5.17 0.37 0.75 0.64 0.9
Derivatized - MS/MS PE NeoGram Kit 118 5.01 0.49 0.64 0.63 0.9
Non-derivatized - MS/MS PE NeoBase Kit 654 5.30 0.38 0.54 0.64 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 104 5.02 0.50 0.68 0.65 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 90 4.84 0.40 0.82 0.60 0.9
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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2015 Quality Control Data Summaries of Statistical Analyses 
STEAROYLCARNITINE (μmol C18/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 862 0.64 0.09 0.14 0.63 0.9
Non-derivatized - MS/MS non-kit 203 0.64 0.06 0.10 0.63 0.9
Derivatized - MS/MS PE NeoGram Kit 105 0.63 0.10 0.12 0.61 0.9
Non-derivatized - MS/MS PE NeoBase Kit 685 0.60 0.04 0.06 0.58 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 119 0.58 0.09 0.19 0.55 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 108 0.55 0.05 0.07 0.55 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 0.62 0.04 0.04 0.60 1.0
Lot 1562 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 856 1.55 0.17 0.31 0.63 0.9
Non-derivatized - MS/MS non-kit 205 1.58 0.13 0.23 0.63 0.9
Derivatized - MS/MS PE NeoGram Kit 109 1.52 0.20 0.23 0.61 0.9
Non-derivatized - MS/MS PE NeoBase Kit 704 1.55 0.11 0.16 0.58 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 116 1.44 0.16 0.33 0.55 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 1.42 0.09 0.12 0.55 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 47 1.59 0.08 0.09 0.60 1.0
Lot 1563 - Enriched 3.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 844 3.19 0.33 0.59 0.63 0.9
Non-derivatized - MS/MS non-kit 205 3.40 0.25 0.44 0.63 0.9
Derivatized - MS/MS PE NeoGram Kit 110 3.12 0.31 0.41 0.61 0.9
Non-derivatized - MS/MS PE NeoBase Kit 690 3.30 0.22 0.31 0.58 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 116 3.04 0.28 0.68 0.55 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 3.11 0.21 0.29 0.55 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 50 3.49 0.23 0.24 0.60 1.0
Lot 1564 - Enriched 5.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 851 5.09 0.53 0.93 0.63 0.9
Non-derivatized - MS/MS non-kit 210 5.35 0.37 0.73 0.63 0.9
Derivatized - MS/MS PE NeoGram Kit 109 5.06 0.60 0.72 0.61 0.9
Non-derivatized - MS/MS PE NeoBase Kit 695 5.33 0.32 0.47 0.58 0.9
Derivatized - MS/MS Chromsystems MassChrom Kit 117 4.97 0.52 1.00 0.55 0.9
Non-derivatized - MS/MS Chromsystems MassChrom Kit 107 4.82 0.33 0.44 0.55 0.9
Non-derivatized - MS2 Screening Neo (MS-Neo) Siemens 48 5.55 0.32 0.34 0.60 1.0
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17hh. 2015 Quality Control Data Summaries of Statistical Analyses 
HYDROXYSTEAROYLCARNITINE (μmol C18OH/L blood)
Lot 1465 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 609 0.01 0.01 0.02 0.01 0.6
Non-derivatized - MS/MS non-kit 95 0.01 0.00 0.01 0.01 0.5
Derivatized - MS/MS PE NeoGram Kit 121 0.01 0.01 0.01 0.01 0.6
Non-derivatized - MS/MS PE NeoBase Kit 542 0.00 0.00 0.00 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 84 0.01 0.01 0.01 0.02 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 85 0.01 0.00 0.01 0.01 0.5
Lot 1466 - Enriched 0.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 614 0.31 0.06 0.11 0.01 0.6
Non-derivatized - MS/MS non-kit 98 0.27 0.03 0.11 0.01 0.5
Derivatized - MS/MS PE NeoGram Kit 128 0.31 0.05 0.07 0.01 0.6
Non-derivatized - MS/MS PE NeoBase Kit 535 0.28 0.02 0.04 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 90 0.35 0.10 0.15 0.02 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 89 0.26 0.04 0.12 0.01 0.5
Lot 1467 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 615 0.61 0.09 0.22 0.01 0.6
Non-derivatized - MS/MS non-kit 96 0.52 0.07 0.23 0.01 0.5
Derivatized - MS/MS PE NeoGram Kit 127 0.60 0.08 0.12 0.01 0.6
Non-derivatized - MS/MS PE NeoBase Kit 537 0.55 0.05 0.08 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 87 0.67 0.11 0.20 0.02 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 88 0.48 0.08 0.23 0.01 0.5
Lot 1468 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 594 0.94 0.13 0.27 0.01 0.6
Non-derivatized - MS/MS non-kit 98 0.80 0.08 0.40 0.01 0.5
Derivatized - MS/MS PE NeoGram Kit 130 0.91 0.11 0.18 0.01 0.6
Non-derivatized - MS/MS PE NeoBase Kit 540 0.85 0.07 0.13 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 86 0.99 0.11 0.30 0.02 0.7
Non-derivatized - MS/MS Chromsystems MassChrom Kit 87 0.73 0.10 0.37 0.01 0.5
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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HYDROXYSTEAROYLCARNITINE (μmol C18OH/L blood)
Lot 1561 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 627 0.01 0.01 0.01 0.01 0.7
Non-derivatized - MS/MS non-kit 136 0.01 0.00 0.01 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 96 0.01 0.01 0.01 0.02 0.6
Non-derivatized - MS/MS PE NeoBase Kit 586 0.00 0.00 0.01 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 99 0.01 0.00 0.01 0.03 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 93 0.00 0.00 0.00 0.00 0.5
Lot 1562 - Enriched 0.25 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 631 0.18 0.03 0.06 0.01 0.7
Non-derivatized - MS/MS non-kit 135 0.17 0.03 0.12 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 99 0.18 0.04 0.04 0.02 0.6
Non-derivatized - MS/MS PE NeoBase Kit 566 0.15 0.02 0.02 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 107 0.19 0.03 0.07 0.03 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 96 0.12 0.02 0.04 0.00 0.5
Lot 1563 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 648 0.68 0.09 0.20 0.01 0.7
Non-derivatized - MS/MS non-kit 135 0.70 0.11 0.45 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 98 0.66 0.09 0.12 0.02 0.6
Non-derivatized - MS/MS PE NeoBase Kit 568 0.60 0.04 0.07 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 110 0.69 0.10 0.19 0.03 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 100 0.52 0.05 0.15 0.00 0.5
Lot 1564 - Enriched 1.5 μmol/L blood
METHOD N Mean
Average Within  
Lab SD Total SD Y- Intercept* Slope
Derivatized - MS/MS non-kit 628 1.00 0.12 0.26 0.01 0.7
Non-derivatized - MS/MS non-kit 135 1.02 0.10 0.70 0.01 0.7
Derivatized - MS/MS PE NeoGram Kit 99 0.97 0.14 0.20 0.02 0.6
Non-derivatized - MS/MS PE NeoBase Kit 592 0.89 0.06 0.12 0.00 0.6
Derivatized - MS/MS Chromsystems MassChrom Kit 107 0.96 0.12 0.29 0.03 0.6
Non-derivatized - MS/MS Chromsystems MassChrom Kit 97 0.76 0.09 0.19 0.00 0.5
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched concentrations and extrapolating the regression 
to the Y-axis.
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Table 17ii. 2015 Quality Control Data Summaries of Statistical Analyses 
24:0-LYSOPHOSPHATIDYLCHOLINE (μmol 24LPC/L blood)
Lot 14101 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
LC-MS/MS 50 0.09 0.02 0.08 0.12 1.0
FIA-MS/MS 30 0.30 0.09 0.12 0.28 1.4
Lot 14102 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
LC-MS/MS 49 1.10 0.20 0.46 0.12 1.0
FIA-MS/MS 30 1.65 0.29 0.29 0.28 1.4
Lot 14103 - Enriched 5.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
LC-MS/MS 50 4.87 1.05 2.00 0.12 1.0
FIA-MS/MS 30 7.25 1.23 1.23 0.28 1.4
*Estimated by performing a weighted linear regression analysis of mean reported concentrations versus enriched
concentrations and extrapolating the regression to the Y-axis.
Summary Report 113
Table 17jj. 2015 Quality Control Data Summaries of Statistical Analyses 
26:0 LYSOPHOSPHATIDYLCHOLINE (μmol 26LPC/L blood)
Lot 14101 - Nonenriched 0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
LC-MS/MS 50 0.06 0.01 0.08 0.08 0.9
FIA-MS/MS 40 0.26 0.11 0.12 0.27 1.1
Lot 14102 - Enriched 1.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
LC-MS/MS 50 1.00 0.14 0.24 0.08 0.9
FIA-MS/MS 40 1.34 0.32 0.40 0.27 1.1
Lot 14103 - Enriched 5.0 μmol/L blood
METHOD N Mean
Average Within 
Lab SD Total SD Y- Intercept* Slope
LC-MS/MS 50 4.51 0.46 0.84 0.08 0.9
FIA-MS/MS 39 5.61 0.99 1.55 0.27 1.1
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